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ABSTRACT 
 
Aging greatly contributes to increased susceptibility to influenza infection. To effectively 
protect against influenza-related complications and mortality, a robust, yet controlled, 
cellular and humoral immune response is critical. CD4 T cells aid in carefully orchestrating 
the balance between inflammatory and anti-inflammatory influenza responses. With this 
research, we examine how the aged environment impacts these responses and CD4 T 
cell differentiation following influenza infection in aged mice. In this thesis, we show that 
the aging environment compromises the ability of CD4 T cells to differentiate into 
functional subsets, resulting in a multitude of dysregulated responses including, delayed 
viral clearance and prolonged inflammation. Priming CD4 T cells using vaccination, 
however, can significantly reduce inflammation, increase survival, and promote a balance 
between inflammatory CD4 T cell subsets. There is a significant reduction in TGF-β with 
vaccination, which reduces the amount of regulatory CD4 T cells in aged mice, necessary 
to have an effective inflammatory response. TGF-β reduction by neutralization reduces 
IFN-γ in aged mice after infection. Even further, we examine how inflammatory and 
regulatory CD4 T cells are affected after eliminating senescent cells, major contributors 
to the aged environment. Using the senolytic cocktail D+Q, regulatory CD4 T cells and 
TGF-β are reduced, suggesting that the senescent environment could be effecting CD4 
T cell responses to influenza. This research is the first examine the relationship between 
senescence and CD4 T cell differentiation. Collectively, this research shows the aged 
environment can be overcome to promote regulated influenza responses with aging.  
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INTRODUCTION 
 
CHAPTER ONE 
 
Health-span and the Characterization of Aging 
 
For decades, the complex processes of aging have perplexed the medical and scientific 
communities. Many questions still remain, especially in the context of immunity and how 
to define, characterize, and prevent aging of the immune system. Through a now growing 
and steady progression of research, we are well on our way to identifying many functional, 
phenotypic, and genetic biomarkers of aging that will dramatically shape the way age-
related diseases and healthcare are approached.  
 
One of the first observations that aging was not simply a chronological process, but rather, 
highly plastic was seen in rats fed a calorically restricted diet, without malnutrition, that 
lived significantly longer compared to those fed ad libitum (McCay et al. 1939). Years 
later, Hayflick defined aging as a process by which cells can only divide a finite number 
of times before reaching a state of irreversible exhaustion (Hayflick and Moorhead 1961; 
Hayflick 1964). These early examples provided the first evidence to support that aging in 
itself is its own unique multifaceted process. Nearly 80 years later we have begun to tease 
apart the role of caloric restriction and other methods of controlling aging in chronic age-
associated diseases. However, little work has been done to examine the role of aging in 
infectious disease control and recovery. Much is left to be discovered about the effects of 
aging on the immune system and the contributions of the aged environment to immune 
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cell function and differentiation into specialized subsets required for controlling infection, 
thus providing a critical balance between inflammatory signals and anti-inflammatory 
signals to induce tissue repair and recovery.  
 
While much of aging research has centered around extending lifespan, it is clear that 
health span is of even greater importance to ensure that older individuals can live the 
majority of their senior years independently and in good health. The World Health 
Organization estimates that compared to about 900 million in 2015, the global population 
over the age of 60 will nearly double to about two billion people by the year 2050 (WHO 
2018a). Moreover, within this population, the number of individuals 80 years of age and 
above will quadruple to about 395 million. Not only does this represent the increased need 
for more effective methods of healthcare as we age, but also the future economic burden 
aging will place on the world.  
 
Despite aging being a multifaceted process independent of age, much of healthcare is 
centered around diagnosis and treatment based on chronological age. However, while 
two individuals may be 80 years of age, one may be a healthy running enthusiast and 
completely physically independent, while the other could be suffering from disease-
related complications and wheelchair bound requiring 24/7 care. As a result, we must 
approach the science of aging from a systematic perspective, assessing each 
compartment individually before applying it to the broader aging topic as a whole.  
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A critical point that all researchers and clinicians need to consider when approaching 
aging-based research is that chronological age does not always correlate with biological 
age. In other words, we must look at aging as its own ailment affecting different bodily 
systems in different ways. With our research, we have shown that although various 
systems age differently within the body, there are commonalities which serve as powerful 
pieces of evidence and insights into the mechanisms of aging. We have seen that there 
is not only a contribution of aging cells themselves to disease, but also the aged 
environment they create on otherwise healthy fully functional cells that influence their 
differentiation and function. In this thesis we examine the effects of aging on the immune 
cell compartment, CD4 T cells in particular, as they have been linked not only to many 
chronic age-related diseases and cancers, but especially for their “helper” role in 
infectious immunity. In our model, we use influenza to study aging and its effect on CD4 
T cells.  
 
Influenza and Aging 
 
Aging impacts nearly all components of the immune system rendering individuals more 
susceptible to bacterial and viral pathogens. Not surprisingly, morbidity and mortality from 
infectious diseases is greatly increased with age; influenza (flu) and pneumonia being 
among the top killers of people over 65 years of age in the U.S. (Heron 2013). Flu is very 
problematic, especially for the elderly, with over 90% of flu-related deaths occurring in 
this population. This often leaves individuals physically impaired and reliant on outside 
assistance for the remainder of their lives (Thompson et al. 2003). Interestingly, despite 
increased rates of flu vaccination in the aged population, they remain one of the most 
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affected by flu, indicating that we must create new strategies for preventative care that 
are based on the specific declines in the aged immune system. To do this, however, we 
must first understand how the immune system declines, especially in those cell types 
responsible for controlling and regulating flu-mediated responses. We do know based on 
the work in this thesis and the work published by others that CD4 T cells change with 
aging, as do the kinetics of the immune response to flu.  
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CHAPTER TWO 
 
Age-related Changes in CD4 T Cells  
 
While flu-related deaths can be caused by many factors, age-related declines in immune 
function contribute significantly and lead to multiple age-related manifestations such as 
delayed and reduced signaling and cytokine secretion by CD4+ T cells in response to flu 
antigens (Garcia and Miller 2001). This, in turn, results in diminished cellular and humoral 
immunity including reduced B cell responses and defective germinal center formation, or 
sites where mature B cells mature and proliferate, as well as dysregulated orchestration 
and recruitment of inflammatory cells that aid in viral clearance and recovery (Ginaldi et 
al. 1999; Lefebvre, Masters, et al. 2016). CD4+ T cells are also essential for robust CD8+ 
T cells responses, which are crucial for flu viral clearance. It has been demonstrated using 
transgenic mouse models that depletion of CD4+ T cells results in a reduction in the 
recruitment of CD8+ T cells to sites of infection and even further, delayed flu viral 
clearance (Beuneu, Garcia, and Bousso 2006; Castellino et al. 2006; Riberdy et al. 2000; 
Allan et al. 1990).  
  
CD4+ and CD8+ T cells are appreciated for their diverse T cell receptor repertoire that 
allows for recognition of a myriad of epitopes on any given pathogen. Experimental 
studies, however, have shown this overall repertoire diversity significantly deceases with 
age (Johnson et al. 2012; Naylor et al. 2005). Moreover, the number of naïve CD4+ T 
cells decreases leading to a  higher frequency of memory CD4+ T cells in the periphery, 
further reducing the ability of aged CD4+ T cells in mice and humans to respond to new 
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pathogens (Moro-Garcia, Alonso-Arias, and Lopez-Larrea 2013). Thymic involution plays 
a role in the population dynamics of CD4+ T cells, however, there are differences in the 
maintenance of peripheral CD4+ T cells between mice and humans. The peripheral 
diversity of CD4+ T cells in mice is more dependent on thymic output, whereas human 
CD4+ T cell diversity is instead heavily dependent on peripheral maintenance (den Braber 
et al. 2012). In addition, mouse studies have shown the prolonged life-span of naïve CD4+ 
T cells itself could cause intrinsic defects in function. A reduction in the levels of Bim, a 
pro-apoptotic protein in the Bcl family, correspond with apoptotic resistance and mediate 
longer CD4 T cell lifespan in the periphery (Tsukamoto et al. 2010). Although this 
contributes to overall CD4+ T cell homeostasis, longer-lived naïve CD4+ T cells 
demonstrate functional defects including reduced proliferation and IL-2 production 
(Tsukamoto et al. 2009). These age-related decrements result in poor CD4+ cell 
responses to flu infection.  
 
Since CD4+ T cells are necessary for robust humoral and cell-mediated flu responses, 
research investigating the rate and magnitude of these age-related changes throughout 
the course of infection is of great significance. In order to properly study the magnitude of 
the response to flu, the primary organs involved must be studied including the lymphoid 
organs and lungs. As a result, human research examining CD4+ T cell deficits during flu 
infection has some important caveats. First, it is often difficult to obtain samples other 
than peripheral blood from living young and aged individuals, which limits the ability to 
examine differences that occur within the lymphoid organs and lungs. Second, it is difficult 
to determine the initial time and peak of infection and corresponding CD4+ T cell 
	 7	
responses when only peripheral blood is available. Third, although we can obtain much 
information from peripheral blood CD4+ T cells, and in fact, most studies used to 
determine clinical outcomes and response to vaccination have been performed using 
peripheral blood CD4+ T cells, it is not always clear if peripheral responses are directly 
related to the CD4+ T cell response within tissues such as the lung, which is the primary 
site of influenza infection. 
 
Only recently have researchers begun to examine early time points and the full kinetics 
of flu infection in young adults who volunteer to be infected with the flu (Park et al. 2018). 
It would be, however, certainly unethical to utilize this same research model in the study 
of the vulnerable aged population who may not be able to survive the course of infection. 
Thus, the clinical importance of these human studies may not be completely applicable 
to the elderly population due to the multitude of changes that occur to the immune system 
with aging. This leaves the majority of human research regarding CD4+ T cell changes 
during flu infection to be focused on peripheral blood CD4+ T cells during flu recovery or 
using vaccination responses as predictive markers for infection responses. Although 
mouse and human CD4+ T cell responses exhibit some inherent differences, mouse 
models have been employed to gain a more in depth understanding of age-related 
changes within the CD4+ T cell compartment. Studies have revealed both cell intrinsic 
and extrinsic factors that contribute to age-related decrements in CD4+ T cell function 
within lymphoid organs and infected lung tissue (Maue et al. 2009). Understanding the 
impact of age-related changes in CD4+ T cells and other components of the adaptive 
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immune system will aid in developing better pharmacological and medical interventions 
and treatment of flu infection in older populations.  
 
Magnitude of CD4+ T cell Responses After Flu Infection 
 
Differentiation and Function of CD4+ T Cell Subsets Following Flu Infection 
 
CD4+ T cell differentiation and functional quality is an important component for efficient 
clearance of flu virus from the lungs. Early mouse studies demonstrated the complexity 
of this response using CD4+ T cell depleting antibodies as well as MHC class II knockout 
mice (Topham et al. 1996; Allan et al. 1990). In these models, there is a delay in viral 
clearance in the absence of CD4+ T cells. Others have also shown a reduction in 
necessary inflammatory mediators and in the numbers of cytotoxic CD8+ T cells present 
at the infection site in the absence of CD4+ T cells (Mozdzanowska et al. 1997; 
Mozdzanowska, Maiese, and Gerhard 2000; Wells, Albrecht, and Ennis 1981; Bourgeois 
et al. 2002).  Taken together, this suggests that CD4+ T cells in the lung during flu infection 
contribute to the cytokine milieu necessary to promote and enhance cellular immunity and 
efficient clearance of the virus. Furthermore, it has been shown more recently, that 
without CD4+ T cells there is a reduction in germinal center formation (Brown, Roman, 
and Swain 2004) as well as antibody production from B cells (Mozdzanowska et al. 2005). 
Indeed, CD4+ T cells have functions that promote both cellular as well as humoral 
immunity (Luckheeram et al. 2012).  
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While there are numerous subsets of CD4+ T cells whose functions are key in various 
types of immunity, there are several effector types that have been especially implicated 
in the initial effector response to influenza and viral clearance, as shown in Table 1. 
Initially, the CD4+ T cell compartment is comprised predominantly of a naïve population 
that in young mice rapidly proliferates and differentiates into appropriate antigen-specific 
effector subsets (Lanzer et al. 2014). This is largely supported by thymic output of 
positively selected self-tolerant CD4+ T cells. In young mice, the peak of CD4+ T cell 
numbers in the lung occurs just before flu viral clearance and results from effective 
priming by antigen presenting cells (APCs) leading to expansion of virus-specific effectors 
(Lefebvre et al. 2012). The flu-specific population consists of CD4+ T cells from all of the 
subsets described in Table 1 throughout the course of infection, highlighting the fact that 
these uniquely specialized subsets work collectively to carefully regulate the response to 
flu (Lefebvre and Lorenzo, et al. 2016).  
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CD4 T cell subset Role in influenza immunity  
  Function: Cytokine/Molecule Secretion: 
Naïve, T0 
Differentiates into various subsets dependent on cytokine 
milieu and environmental responses following recognition 
of viral peptide antigens presented on MHCII molecules 
by APCs   
--- 
Cytotoxic, THCTL 
Responds directly to virally infected cells via MHCII 
dependent mechanism involving Fas/Fas ligand mediated 
apoptosis and cytotoxic granule exocytosis  
Granzyme B and 
Perforin 
Type 1 helper, TH1 
Promotes activation of CD8
+
 T cells, macrophages, non-
hematopoietic lung epithelial cells 
IFN-γ, IL-2, and 
TNF-α 
T follicular helper, TFH 
Promotes germinal center formation in lymph nodes, B 
cell differentiation, and high-affinity antibody generation IL-4 and IL-21 
Regulatory, Treg 
Maintains homeostasis of lung mucosal environment and 
dampens inflammatory response, necessary for 
resolution and healing after viral clearance 
IL-10 and TGF-β 
Memory, Tmem 
Responds more rapidly than naïve CD4
+
 T cells to 
secondary challenge or to infection following vaccination 
and differentiates into various subsets dependent on 
cytokine milieu and environmental responses  
--- 
 
Table 1. Important subsets of CD4 T cells that mediate regulation and suppression of 
influenza responses in the lung and draining lymph node. APC, antigen presenting cell; 
MHCII, major histocompatibility complex class II.  
 
Differentiation of naïve CD4+ T cells residing in the lung draining lymph node into the 
various antigen-specific effector subsets is dependent on presentation of viral antigens 
via MHC class II on APCs bearing cognate antigen, cytokines, and environmental and 
cellular cues. T follicular helper cells (TFH) CD4+ T cells downregulate the chemokine 
receptor CCR7 and begin to express markers such as programmed cell death-1 (PD-1), 
chemokine receptor CXCR5, inducible co-stimulator (ICOS), and the transcription factor 
B-cell lymphoma 6 protein (BCL6) (Choi et al. 2011; Crotty, Johnston, and Schoenberger 
2010; Eto et al. 2011; Johnston et al. 2009). This allows for their entry into the B cell 
follicles in order to ultimately promote the generation of high affinity antibodies (Haynes 
2008; Hardtke, Ohl, and Forster 2005).  
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Expression of other transcription factors, while in the draining lymph node promote 
differentiation into other CD4+ T helper (TH) subsets, while expansion of CD4 TH cells can 
be seen in the lymph nodes and lung tissue after migration. Within the lung, type 1 helper 
CD4+ T cells (TH1), distinguished by upregulated transcription factor T-box expressed in 
T cells (T-bet), secrete interferon-γ (IFN- γ) and tumor necrosis factor-α (TNF-α), along 
with interleukin-2 (IL-2) at the site of infection. These, along with other chemokines, 
promotes recruitment of macrophages as well as proliferation of CD4+ and CD8+ T cells. 
Additionally, in conjunction with their helper functions, CD4+ T cells maintain their own 
ability to directly lyse virally infected cells as cytotoxic CD4+ T cells (THCTL) following up-
regulation of the transcription factor eomesodermin (Brown et al. 2006). Further, 
cytokines secreted by TH1 cells enhance THCTL activity. As depicted in Figure 1 A, the 
peak viral load is approximately 4-6 days post-infection in young mice, with a coinciding 
peak of inflammatory mediators at 6 days post-infection. After this peak, both 
inflammatory mediators and virus in the lungs are reduced until full clearance is reached 
by approximately day 12 post infection in young mice (Lefebvre and Lorenzo, et al. 2016). 
 
As shown in Figure 1 B, there is about a 2:1, TH1:TFH ratio 6 days post-infection, 
increasing to 3:1 by day 12. While the ratio beyond day 12 post infection remains to be 
seen, it is clear that not only the quality, but also quantity of CD4+ TH cells is also important 
during infection. Collectively, in normal young mice, these TH subsets work to promote 
tightly regulated inflammatory responses at various times throughout infection. This 
regulation is important to effectively eliminate virally infected cells through cell-mediated 
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responses, while controlling inflammation and subsequently promoting a healing and 
recovery phenotype after virus has been cleared.  
 
 
 
Figure 1. Summary of young and aged responses to influenza infection. Young (2–3 mo) and aged (18–20 
mo) male C57BL/6 mice were infected with a sublethal dose of H1N1 influenza. Responses were measured 
at time points post infection. Results summarized from original published data (Lefebvre et al. 2016). a) 
Virus quantitation and inflammatory mediators (cytokines and chemokines) were assessed in lung tissue 
and bronchiolar lavage fluid (BAL), respectively. b) Virus in lungs graphed with the ratios of TH1 to TFH CD4 
T cells in the lungs on days 6–12 of infection.  
 
 
Although the majority of CD4+ T cell effector functions have been demonstrated using 
mouse models due to the limited ability to study in vivo human CD4+ T cell responses, it 
is important to recognize that many aspects of CD4+ and CD8+ T cell functions have been 
corroborated in humans as well (McElhaney et al. 2006).  
 
Changes in CD4+ T Cell Subsets With Aging and Their Response to Flu Infection 
 
Aging leads to a multitude of changes in the response to flu infection. While the effect of 
aging on CD8+ T cell responses to flu has been extensively studied (Brown et al. 2006; 
order to ultimately promote the generation of high
affinity antibodies (Haynes 2008; Hardtke et al. 2005).
Expression of other transcription factors, while in
the draining lymph node or later after trafficking to the
lung, promote the differentiation into other CD4? T
helper (TH) subsets. Within the lung, type 1 helper
CD4? T cells (TH1), distinguished by upregulated
transcription factor T-box expressed in T cells (T-bet),
secrete interferon-c (IFN- c) along with interleukin
(IL)-2 at the site of infection. This, along with other
chemokines, promotes recruitment of macrophages as
well as proliferation of CD4? and CD8? T cells.
Additionally, in conjunction with their helper func-
tions, CD4? T cells maintain their own ability to
directly lyse virally infected cells as cytotoxic CD4? T
cells (THCTL) following up-regulation of the tran-
scription factor eomesodermin (Brown et al. 2006).
Further, cytokines secreted by TH1 cells enhance
THCTL activity. As depicted in Fig. 1a, the peak viral
load is approximately 4-6 days post infection in young
mice, with a coinciding peak of inflammatory medi-
ators at 6 days post infection. After this peak, both
inflammatory mediators and virus in the lungs are
reduced until full clearance is reached by approxi-
mately day 12 post infection in young mice (Lefebvre
et al. 2016b).
We have recently examined the ratio of TH1 to TFH
in the lungs following flu infection (Lefebvre et al.
2016b). As shown in Fig. 1b, there is about a 2:1,
TH1:TFH ratio 6 days post infection, increasing to 3:1
by day 12. While the ratio beyond day 12 post
infection remains to be seen, it is clear that not only the
quality but also quantity of CD4? TH cells is also
important during infection. Collectively, in normal
young mice, these TH subsets work to promote tightly
regulated inflammatory responses at various times
throughout infection. This is important to effectively
eliminate virally infected cells through cell mediated
responses, while controlling inflammation and subse-
quently promoting a healing and recovery phenotype
after virus has been cleared.
Although the majority of CD4? T cell effector
functions have been demonstrated using mouse mod-
els due to the limited ability to study in vivo human
CD4? T cell responses, it is important to recognize
that many aspects of CD4? and CD8? T cell functions
have been corroborated in humans as well (McEl-
haney et al. 2006). The presence of CD4? and CD8? T
cells in the blood following vaccination has been
shown as a more accurate readout of vaccination
efficacy and the ability to respond to flu virus. A study
by McElhaney et al. (2006) demonstrated that the
effector function of CD4? and CD8? T cells from flu
vaccinated individuals following ex vivo stimulation
with live flu virus could predict how robust flu
responses would be following infection. Indeed, those
individuals with lower CD4? and CD8? T cell
numbers following ex vivo stimulation with live flu
virus had a higher rate of laboratory diagnosed flu as
opposed to those subjects that had higher CD4? and
CD8? T cell numbers (McElhaney et al. 2006). This
suggests that the number of CD4? and CD8? T cells
could be a better correlate of protection from flu
infection following vaccination. While human studies
have corroborated the findings in murine studies
regarding the importance of CD4? T cells to flu
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Fig. 1 Summary of young and aged responses to influenza
infection. Young (2–3 mo) and aged (18–20 mo) mal C57BL/6
mice were infected with a sublethal dose of H1N1 influenza.
Responses were measured at time points post infection. Results
summarized from original published data (Lefebvre et al.
2016b). a Virus quantitation and inflammatory mediators
(cytokines a d chemokines) were assessed in lung tissue and
bronchiolar lavage fluid (BAL), respectively. b Virus in lungs
graphed with the ratios of TH1 to Tfh CD4 T cells in the lungs on
days 6–12 of infection
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Ely et al. 2007; Hufford et al. 2015), the impact of aging on CD4+ T cells is less well 
understood. Since CD4+ T cells are crucial for the plethora of responses to flu as outlined 
above, age-related changes in CD4+ T cells will have vast effects on flu immune 
responses. This aged CD4 T cell response is of great clinical importance since flu 
infection can also increase the risk for other opportunistic and secondary bacterial 
infections to occur in susceptible aging populations in both mouse models and humans 
(Lefebvre and Lorenzo, et al. 2016; Haynes et al. 2012; Joseph, Togawa, and Shindo 
2013). 
 
Previous in vivo and in vitro studies have shown that age-related changes in murine CD4+ 
T cells influence a variety of functions. The ability of the T cell receptor (TCR) to signal is 
impaired with aging as demonstrated by reduced immunological synapse formation, the 
interface at which T cells and antigen presenting cells meet (Tamir et al. 2000; Garcia 
and Miller 2001, 2002). In addition, there are defects in activation, differentiation, and 
proliferation of CD4+ T cells taken from aged mice (Haynes and Eaton 2005). CD4+ T 
cells also have a reduced capacity to produce IL-2 upon antigenic stimulation with age 
(Linton et al. 1996) and to provide cognate help to B cells, thus impacting humoral 
immunity (Eaton et al. 2004). Along with these T cell-intrinsic differences, it has been 
shown that the murine aged microenvironment also negatively impacts CD4+ T cell 
function. Young CD4+ T cells when transferred into aged hosts demonstrated a reduction 
in recruitment, proliferation, and differentiation when compared to donor CD4+ T cells 
transferred into young hosts (Lefebvre and Masters, et al. 2016). Thus, it is clear 
decrements in CD4+ T cells with aging is multifaceted with both intrinsic and extrinsic 
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factors involved, however mechanisms involved in extrinsic influences remain to be 
elucidated. 
 
Interestingly, the total number of CD4+ T cells in the lungs after flu infection is not different 
between young and aged mice, however, the ratio of TH subset distribution is impacted 
by aging (Lefebvre and Lorenzo, et al. 2016; Marshall et al. 2011). Young mice have 
nearly twice as many TH1 cells (indicated by transcription factor T-bet) as TFH (indicated 
by transcription factor BCL6), which is necessary for creating a robust initial inflammatory 
response in the lung (Lefebvre and Lorenzo, et al. 2016). Aged mice not only have a 
greater proportion of memory cells (Tmem), but an approximately 1:1 ratio of TH1 to TFH in 
the lungs during flu infection at day 6 which remains constant through day 12 post 
infection as shown in Figure 1 B. This skewed ratio is not only represented in the overall 
CD4+ population, but also in the flu nucleoprotein (NP)-specific population as well, which 
will be further described in this thesis (Lefebvre and Lorenzo, et al. 2016). Thus, aged 
mice do not have the same CD4 T cell subset differentiation and distribution as young 
mice following infection. Furthermore, there is a significant delay in the appearance of flu-
specific TH1 effector CD4+ T cells in the lungs following infection of aged mice, which may 
contribute to slower viral clearance (Lefebvre, Lorenzo, et al. 2016; Lanzer et al. 2014).  
 
With regard to TFH, aged mice have increased TFH both by percent and number when 
compared to young mice at baseline as well as on days 7, 10, and 12 post infection 
(Lefebvre, Lorenzo, et al. 2016; Lefebvre, Masters, et al. 2016). The finding of more TFH 
in aged mice may seem counterintuitive, since it is known that aged mice have less robust 
	 15	
humoral responses (Eaton et al. 2004; Lefebvre, Masters, et al. 2016), but, it is important 
to note that despite an increase in TFH cells, the aged TFH do not appear to be as functional 
and provide reduced levels of help to B cells when compared to young TFH. Additionally, 
within the aged TFH population there is an increase in T follicular regulatory cells (TFR) 
which can function to inhibit TFH helper activity within the germinal center (Lefebvre, 
Masters, et al. 2016). Therefore, the increase in TFH in aged mice does not actually 
contribute to improving the immune response.  
 
The initial kinetics and clearance of flu virus is indicative of recovery from flu infection 
(Lefebvre, Lorenzo, et al. 2016; Kanegai et al. 2016). Flu infection is a much more severe 
disease with aging and is characterized by slower viral clearance and significantly greater 
weight loss, a marker of pathogenicity in mouse models (Lefebvre, Lorenzo, et al. 2016; 
Lefebvre, Masters, et al. 2016). Inflammatory mediators, including cytokines and 
chemokines, linger in the bronchiolar lavage fluid (BAL) of aged mice long after they have 
returned to baseline in young mice (Figure 1 A). By day 12 post-infection, young mice 
have cleared the virus, resolved inflammation and have returned to their pre-infection 
weight. In contrast, viral copy number in aged lungs remain elevated at this time point 
and inflammation has not yet been resolved (Lefebvre, Lorenzo, et al. 2016). While aging 
impacts both TH subsets, aged mice exhibit enhanced TFH and reduced TH1 generation, 
as mentioned previously (Lefebvre, Lorenzo, et al. 2016). It remains to be investigated 
whether this preference for TFH differentiation is intrinsic to aged CD4+ T cells or if it is 
induced by the aged microenvironment. More research is necessary to determine the 
cause and consequence of this altered differentiation. 
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Examination of human peripheral blood cells has allowed us to study the humoral 
responses as well as the circulating cellular responses to flu with age. It has been 
demonstrated that older adults have a CD4+ T cell compartment skewed towards mostly 
regulatory, memory, and Type 2 like (TH2) helper T cells at baseline as well as following 
flu vaccination (McElhaney et al. 2016; McElhaney, Coler, and Baldwin 2013). While 
these subsets may be important in the resolution of flu infection, the reduction in the initial 
effector response could be a driving force leading to poor viral clearance resulting in much 
longer recovery time, increased lung damage, and potentially increasing the risk of 
secondary bacterial infections. While we and others have begun to more deeply examine 
the mechanisms, both intrinsic and extrinsic, affecting this CD4 T cell differentiation, much 
remains to be investigated. It is essential to determine these mechanisms first in order to 
begin pre-clinical development of therapeutics aimed at improving the aged response to 
flu infection. 
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CHAPTER THREE 
 
Influenza Virus   
 
 
The influenza A virus is part of the Orthomyxoviridae family of viruses characterized by 
having a negative-sense, single stranded RNA genome composed of eight segments that 
encode for 11 viral proteins (Mikilásová et al. 2000). It is also known to be highly 
associated with worldwide human pathogenesis, although it also infects a wide variety of 
birds and mammals. Influenza A strains are further characterized by the subtype of 
surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) (Bouvier and Palese 
2008). It has a spherical viral envelope, which displays HA, NA, as well as matrix protein 
2 (M2), which is an ion channel that aids in regulation of viral pH (Pinto et al. 1992), all 
embedded in its lipid membrane.  
 
HA binds to sialic acid residues on the surface of epithelial cells residing in the upper and 
lower respiratory tract (Hay et al. 1977; Weis et al. 1988). The virus is then internalized 
by clatharin-mediated endocytosis and macropinocytosis (Banerjee et al. 2013; de Vries 
et al. 2013). NA is essential for both viral entry and release. As HA binds to the surface 
sialic acid on epithelial cells, it is quickly taken up by the cell where NA can cleave the 
sialic acid residue from the galactose linkage freeing the virus particles from the cell 
surface receptors (Coleman et al. 1983; Lai et al. 2017). After the viral particles enter the 
cell they are sorted to late endosomes or mature macropinosomes, exposing them to low 
pH. This leads to a conformational change allowing membrane fusion of the viral envelope 
to the endosome and release of the eight viral ribonucleoproteins to the nucleus while the 
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matrix protein 1 (M1) remains in the cytosol (Banerjee et al. 2013). Once new viral 
progeny form after using host cell machinery to replicate, NA will cleave the sialic acid 
residues to release virions outside the cell. HA and NA are known to be very immunogenic 
parts of the influenza virus, and as such are used as major components of vaccination 
strategies and treatments, such as the popular NA inhibitor Oseltamivir.  
 
While the external portions of the virus are responsible for fusion and entry into the host 
cells and mediating the delivery of viral RNA, the internal portion is made up of key 
components that allow for viral replication and stability. M1, which coats the internal 
portion of the viral lipid envelope provides structural integrity and also enhances transport 
of viral ribonucleoproteins through the cytosol into the nuclear pores (Martin and Helenius 
1991). Each of the eight segments of RNA are encapsulated by viral nucleoprotein (NP) 
forming a ribonucleoprotein complex (Baudin et al. 1991). Each complex also contains its 
own polymerase complex consisting of three subunits: polymerase PB1, polymerase 
PB2, and acid polymerase (PA) (Baudin et al 1991; Dou et al. 2018). The eight segments 
begin transcription as soon as they enter the cell nucleus and serve as templates for 
mRNA synthesis. Each of these segments encodes for each of the viral proteins: 1) HA, 
2) NA, 3) NP, 4) PB1, 5) PB2, 6) PA, 7) M, which gets spliced into M1 and M2, as well as 
8) the nonstructural proteins (NS), which gets spliced into NS1 and NS2. The NS1 protein 
inhibits antiviral interferon alpha and beta production, while NS2 aids in the export of the 
viral ribonucleoproteins from the nucleus back to the cytoplasm (García-Sastre et al. 
2001; Kochs et al. 2007; Salahuddin and Khan 2010).   
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Due to high mutation rates, mainly caused by error-prone nucleic acid polymerases and 
RNA recombination in vivo, new strains appear each year posing a new threat to the 
global populations. Antigenic drift results in minor mutations in the HA and NA subunits 
of the viral envelope. Although these are small mutations that generally have similar 
antigenic properties, it allows the flu virus to rapidly change and can result in epidemics 
each year around the world. Larger changes in nucleic acid called antigenic shift results 
in pandemic strains in which brand new HA and NA subunits are created through mutation 
or recombination. Antigenic shift is particularly dangerous, although it occurs much less 
frequently, having only been recorded four times, resulting in a pandemic within the last 
100 years (CDC 2019a). Even flu strains that have drifted slightly pose a threat to 
vulnerable populations, especially the elderly or immunocompromised people. Although 
in this thesis work influenza is used as the model pathogen, this work can translate to 
many other bacterial and viral pathogens. The virology and pathogenesis of flu outlined 
above makes it a powerful model for the study of the aged immune system.    
 
 
Worldwide Initiatives to Control Flu Epidemics and Pandemics 
 
 
The flu is not a modern disease; in fact, it is suspected that epidemics and pandemics of 
flu infection have affected mankind for thousands of years as historians and scientists 
uncover observational reports of flu symptoms and pathogenesis dating as far back as 
the times of Hippocrates (Hirsch 1883; Patterson 1985; Taubenberger et al. 2010). With 
the advancements in scientific research and medicine, we have been able to better 
identify and monitor outbreaks. There have been many epidemics of flu around the world, 
however the most notable pandemics in the modern era have occurred, so far, in 1918, 
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1957, 1968, and 2009, each having a world-wide death toll of one million or more 
individuals (CDC 2018).  
 
The flu pandemic of 1918, otherwise known as the Spanish Flu, was particularly 
devastating and arguably the worst pandemic in the last 100 years. It was responsible for 
infecting nearly a third of the world’s population and killing tens of millions of people (WHO 
2018b). This pandemic spurred a large amount of flu-based scientific and medical 
research as people raced to determine the etiology and isolate the flu virus itself. Careful 
reports, although somewhat contradictory to what we know now with advanced 
technologies, were published describing the clinical pathology and mode of transmission 
(Shope 1931a). It was shown that there were potentially different strains that had varying 
levels of severity and mortality, also dependent on species of animal infected, and it was 
proposed that the pathogen responsible for causing the flu was a virus, not bacterial 
infection (Lewis and Shope 1931). Bacterial infection caused by various pneumococci, 
however, were highly prevalent in infected animals, indicating that secondary bacterial 
infections could accompany the flu viral infection (Shope 1931a). More importantly, from 
a clinically relevant perspective, it was discovered that serum from recovered animals 
neutralized infectious flu material in vitro (Shope 1931b). This neutralization was later also 
seen using in vivo models as well (Dochez et al. 1933; Smith et al 1933; Shope 1934).  
 
Ongoing research at the time led to worldwide public health, medical, and scientific 
initiatives for preventative care and treatment. In 1947, the Global Influenza Surveillance 
Program was established by the WHO Interim Committee of the United Nations, which 
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was at the forefront of tracking the flu virus around the world (WHO 2018b). It grew to a 
network of 26 collaborating laboratories by 1952 (WHO 2018b). Today, the program is 
called the Global Influenza Surveillance and Response System, which is a conglomerate 
of 153 institutions in 114 countries (WHO 2018b). The goal of the program is to rapidly 
share influenza-related data, viruses, and outbreak warnings with the hopes of minimizing 
the risk of epidemics or another devastating pandemic, and provide information to 
develop flu seasonal vaccines for countries around the world.  
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CHAPTER FOUR 
 
 
The Development of Flu Vaccination  
 
 
In the 1930s and 1940s, the flu virus was cultured for the first time and the first flu vaccine 
was generated and tested in clinical trials. In the first published studies, human throat 
washings from individuals infected with the flu were used to infect ferrets and glycerolated 
material from those ferrets were saved for experimentation in chicken eggs (Burnet 1940). 
Fertilized chicken eggs were then drilled into and received amniotic inoculation with the 
glycerolated flu material. The eggs were re-sealed for a three-day incubation and 
significant pathology as well as virus was observed in the embryos (Burnet 1940). This 
was an incredible turning point for influenza research as it was shown that the flu could 
be easily replicated in large quantities making it very useful for future studies, especially 
in considering the commercializing a vaccine for the public.  
 
The first vaccine was composed of flu particles that were inactivated using small amounts 
of formalin and high speed centrifugation (Stanley 1945). This was licensed for use in 
1945 in the US (CDC 2019b). While showing strong correlates of protection in many 
studies and no significant impact in others, several very important hypotheses were 
developed. First, it was supposed that the flu vaccination may be more effective if there 
was an adjuvant present to enhance the immunogenic response (Francis 1953). Second, 
there could be an additive effect of herd immunity, where vaccination of even a few can 
have a significant impact on the entire community limiting infection and protecting 
unvaccinated individuals (Francis 1953). This is especially important when considering 
	 23	
that the studies were performed within the same community. Finally, it was also proposed 
that perhaps the flu mutates at a much more rapid rate than the length of time for vaccine 
formulation, purification, and distribution (Francis 1953). Each of these hypothesis have 
impacted the way we approach vaccination strategies today and what it means to be an 
effective method of disease prevention.  
  
Following years of trial and error in predicting potential flu strains to formulate a new 
seasonal vaccination, there exists a number of strategies for flu vaccine production since 
it was first created. For the 2019—2020 year, there are currently 9 different types of 
vaccination formulations available with slightly varying methods of production (CDC 
2019c). Out of these, only two, Fluzone High-Dose (Sanofi Pasteur) and Fluad (Sequiris), 
are specifically recommended for individuals ≥65 years of age in the United States (CDC 
2019c). As a major health concern, it is understandable that the quickest method to 
making a flu vaccine is necessary to prevent devastating pandemics. However, what was 
not considered, given the research technologies in the 30s and 40s, was the decrements 
of the aged immune system and how that impacts vaccine efficacy.  
 
Vaccination in the ≥65 Year Old Population  
 
Surface HA is one of the primary targets of flu-induced neutralizing antibody responses 
and remains the basis for almost all vaccination strategies today (except for the live 
attenuated version; FluMist Quadrivalent (AstraZeneca)) (CDC 2019c). As a result, 
vaccine efficacy is measured by two standards; a) the induction of anti-HA antibody 
generated as validated by antibody titers and hemagglutinin inhibition assays and b) the 
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ability to prevent infection and spread of the disease. In general, flu vaccines serve as a 
way to enhance humoral immunity and build immunological memory prior to exposure to 
infection. The recommended vaccination for the ≥65 age group are administered 
intramuscularly and consist mainly of HA molecules that were partially purified from the 
selected current circulating strains (or those of a most similar match).  
 
As mentioned earlier, there are two types of flu vaccines for the ≥65 aged population; 
Fluzone High-Dose (Sanofi Pasteur) and Fluad (Sequiris). Fluzone High-Dose has nearly 
four times the amount of purified HA antigen than the standard dose flu vaccine, with the 
rationale that higher quantities of antigen will produce a more robust response 
(DiazGranados et al. 2014). The 2019—2020 formulation is a trivalent vaccine containing 
two types of influenza A HAs, one from H1N1 and H3N2, and one type of influenza B HA 
(Sanofi Pasteur 2019). In this vaccine, following the inactivation of the cultured virus with 
formaldehyde and the chemical disruption to split the virus with Triton X-100, the viral 
particles are purified and HA is isolated (Sanofi Pasteur 2019). Even further, it is again 
filtered to obtain higher HA antigen concentrations and to filter out any remaining 
chemicals from processing, although trace amounts may be found in the final product 
(Sanofi Pasteur 2019). The final resulting vaccine contains the purified HAs in sodium 
phosphate-buffered isotonic sodium chloride solution (up to 0.5mL total volume), not 
containing any preservatives in single dose syringes (Sanofi Pasteur 2019). According to 
clinical trials, seroprotective rates in the ≥65 age group were significantly higher when 
compared to those that received the standard flu dose (DiazGranados et al. 2014) (Falsey 
et al. 2009). 
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Fluad has an interesting formulation and unlike any other approved flu vaccine contains 
the adjuvant MF59. It is also a trivalent vaccine, but it is prepared with the MF59C.1 
squalene-based oil and water emulsion (FLUAD Seqirus Inc. 2019). Like Fluzone High-
Dose, the cultured virus is inactivated by formaldehyde (FLUAD Seqirus Inc. 2019). The 
inactivated virus is then concentrated and purified by centrifugation. The surface antigens 
HA and NA are isolated and even further centrifuged for more purification (FLUAD 
Seqirus Inc. 2019). The final vaccine has the flu particles of HA (it is unclear whether or 
not NA is actually purified out of the vaccine formulation or not) and MF59 adjuvant 
without preservatives in a single use 0.5mL dose (FLUAD Seqirus Inc. 2019). Clinical 
trials for the vaccine showed a significant increase in the seroprotective rates that 
persisted for about six months following initial vaccination when compared to un-
adjuvanted vaccine formulation (Otten et al. 2020; Della Cioppa et al. 2012; O’Hagan et 
al. 2014). We will use a similar vaccination construct using flu NP protein and an MF59-
like adjuvant in mice, described later in the thesis.  
 
Adjuvants are designed to enhance the immunogenicity of the antigen being vaccinated 
against. They can be used as an antigen depot, to hold antigen at the site of injection for 
longer periods of time, to enhance antibody responses, to induce the activation of immune 
cells, and to polarize the immune cells to become a particular phenotype. The exact 
mechanism of action of the MF59 adjuvant is still vague, however descriptive research 
has revealed that it is effective at inducing both antibody and CD4 T cell responses (Wack 
et al. 2008). MF59 also gets distributed across several tissues such as muscle, fat, blood, 
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and the liver in mice as early as 4 hours post injection (Dupuis et al. 1999; Ott et al. 1995). 
This, coupled with evidence that supports MF59 is an activator of innate immune cells 
such as monocytes and dendritic cells to enhance inflammatory cytokine secretion and 
cellular recruitment to injection site (Dupuis et al. 2001; Calabro et al. 2011; Dupuis et al. 
1998), suggests that is not simply to serve as an antigen depot, but rather, has a direct 
enhancement on the immune responses. A huge caveat, however, is that these studies 
were not performed in a physiologically aged system. This omission is a very big gap in 
research when we consider that the use of MF59 is to enhance the immunogenicity of flu 
vaccination in the ≥65 aged population. It is also entirely possible that even with an 
adjuvant, there are other intrinsic defects in the aged immune response to flu that cannot 
be recovered simply by giving a vaccination with an adjuvant in every older adult.  
 
Despite seroprotective rates being higher in the ≥65 aged individuals when using these 
two types of vaccines, this population continues to remain one of the most at risk for flu 
related hospitalization and post-hospitalization disability. Most importantly, flu-related 
morbidity and mortality within this particular population has not declined, despite higher 
rates of vaccination within the last decade. This suggests that although we are 
discovering new ways to enhance immunity in older adults through vaccination, a different 
strategy is required as opposed to just enhancing protective antibody production. The 
live-attenuated vaccine formulation known as FluMist Quadrivalent (AstraZeneca) was 
created for this purpose; to enhance cell mediated immunity, however, it is best used 
between the ages of 2 through 49. Furthermore, it is not approved in adults 50-64 or 65+ 
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years of age due to its failure in preventing fever and higher rates of sore throat and other 
adverse effects (AstraZeneca 2019).  
 
With our growing aged population, as described earlier, finding a protective vaccine that 
works well when considering the declines in aged immunity is incredibly important. The 
work described in this thesis aims to fill these gaps in the literature by examining CD4 T 
cells in their response to flu vaccination and infection. It is still not fully understood why 
the age-related declines in CD4 T cell differentiation and function occur. We have used 
flu vaccination followed by infection as a model to study CD4 T cells and the overall aged 
response to flu in this regard. Furthermore, we have used a portion of the NP protein of 
the flu virus, known to enhance CD4 responses (discussed more in the next section), 
coupled with an MF59 like adjuvant, AddaVax as the vaccination strategy.   
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CHAPTER FIVE 
 
 
Immunodominant CD4 T Cell Responses to Flu 
 
 
As mentioned earlier, most flu vaccinations aim to enhance antibody production in 
immunized individuals. In the context of aging immunity, it has been shown, however, that 
antibody responses do not always correlate with protection and that cell-mediated 
responses are a potentially better readout of vaccination efficacy (McElhaney et al. 2006; 
McElhaney et al. 2013; McElhaney et al. 2016). Cell-mediated responses take advantage 
of cross-reactivity between influenza subtypes and conserved proteins on the outer and 
inner portions of the virus. While generating a neutralizing antibody response is important 
in the protection from flu, the ability to generate flu-specific antibodies becomes 
significantly impaired with age (Haynes et al. 2012; Lefebvre et al. 2016).  
 
Following T cell receptor recognition and binding of MHC-peptide complex containing flu 
antigens from antigen presenting cells, CD4 and CD8 T cells will clonally expand from 
naïve into effector cell populations. The primed effector T cells will then migrate from the 
draining lymph node to the lungs where they can exert their effector functions. It has been 
shown that interferon gamma (IFN-γ), IL-10, and granzyme-B, all important in the 
clearance and recovery from flu infection, are better correlates of risk of laboratory 
diagnosed influenza (LDI) (McElhaney et al. 2006; Kumar et al. 2017). In comparing     
IFN-γ:IL-10 ratios ex vivo from re-stimulated PBMCs with live flu virus, the LDI population 
had a ten-fold lower ratio than the non-LDI population (McElhaney et al. 2006). This lower 
ratio indicates that individuals that had higher levels of these cytokines upon ex vivo re-
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stimulation showed lower risk of being diagnosed with the flu. In contrast, pre- and post- 
antibody titers, however, did not distinguish between the LDI and non-LDI populations. 
These cytokines and cytotoxic molecules are secreted by both CD4 and CD8 T cells 
(McElhaney et al. 2006; Kumar et al. 2017).    
 
CD4 T cells, in particular, are known to recognize internalized antigens complexed with 
MHC II presented from the surface of APCs. In classical MHC II presentation, exogenous 
flu virus particles and cell fragments are endocytosed and processed within the APC to 
present on its surface, while more recent reports show that influenza A viruses can directly 
infect dendritic cells, which subsequently endogenously present an even more diverse 
repertoire of viral peptides leading to even stronger CD4 T cell responses (Miller et al. 
2015). This then leads to more diverse epitopes recognized by CD4 T cells and is critical 
to initiate a more robust response to flu. With the decrease in This suggests that our 
current vaccination strategy for the 65+ population may not capable of eliciting a robust 
enough CD4 T cell repertoire to respond to multiple immunogenic flu epitopes.  
 
Studies performed in humans and mice have shown the ability of CD4 T cells to recognize 
nearly 30 different influenza A epitopes, with the majority being from NP and HA proteins 
(Crowe et al. 2006; Babon et al. 2012; Chen et al. 2014; Richards et al. 2018). NP is a 
relatively conserved protein between influenza type A strains and induces a strong CD4 
T cell response in vivo (Hu et al. 2017; Richards et al. 2018). Surprisingly, there have 
been no studies performed that examined the vaccination response, efficacy, or the rate 
of hospitalization in aged adults using NP or other flu peptides to prime the immune 
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system. Although the number of naïve T cells decreases due to thymic involution 
(Jamieson et al. 1999), it has been shown that the overall flu specific CD4 T cell repertoire 
is generally unaffected in aged mice (Lanzer et al. 2014). It has also been shown, 
however, that despite the ability of aged CD4 T cells to generate a sufficient flu-specific 
repertoire, there is a delay in the appearance of flu-specific CD4 T cells into the lung after 
infection (Lanzer et al. 2014). This is a good indication that while there may be various 
CD4 T cell intrinsic defects that occur with aging, as described earlier, one of the major 
contributors to poor CD4 T cell responses to the flu could be extrinsic changes including 
the aging tissue environment, which can have a large impact on CD4 T cells, especially 
through cytokine secretion.  
 
 
Inflammation and CD4 T Cell Responses 
 
CD4 T cells require three key signals in order to clonally expand and differentiate. One is 
the recognition of antigenic peptides through TCR:MHCII interactions required for 
activation of T cells. The second is further signaling through co-stimulatory molecules 
between APCs and T cells providing activation or inhibitory signals, which direct cell fate 
and function (June et al. 1987; Mueller et al. 1989). The third are cytokines and 
chemokines, which provide more signals necessary for differentiation, migration of newly 
generated flu-specific CD4 T cell subsets to the lung where they exert their effector 
functions, and further expansion in the lung as determined by the cytokine environment. 
With aging, chemokine and cytokine signals after flu infection are significantly altered and 
delayed, which affects CD4 T cell differentiation, migration, and expansion (Lefebvre et 
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al. 2012; Lefebvre et al. 2016). Many cell types and their secretion factors contribute to 
these effects and several of them will be discussed in this thesis.  
 
Cellular damage that occurs with flu infection has major implications on lung epithelial 
and endothelial cell integrity. Epithelial cells consist of a multitude of diverse subtype that 
line the nasal, tracheal, and airway tracts such as ciliated cells, secretory cells, and basal 
cells (Denney and Ho 2018). They each have specialized functions that when working 
together create an effective mucosal barrier from airway containments and antigens. With 
flu infection, epithelial cells will secrete a vast array of different cytokines and chemokines, 
of which, some are particularly important in the context of CD4 T cells. As the virus 
spreads killing epithelial cells, it also induces damage to the tight junctions that maintain 
the pulmonary epithelial-endothelial cell barrier (Short et al. 2016). With the destruction 
of the tight junctions and surrounding cells, inflammatory mediators rise sharply as 
damage associated molecular patterns (DAMPs) and pathogen associated molecular 
patterns (PAMPs) are released (Short et al. 2016; Teijaro et al. 2011). Secreted 
chemoattractant proteins signal for the influx of leukocytes, for example, macrophage 
inflammatory proteins (MIPs) and monocyte chemoattractant proteins (MCPs), while 
other secreted interleukins and cytokines important for the differentiation and expansion 
of CD4 T cell effector subsets are also generated. These cytokines are important since 
naïve CD4 T cells will become activated and will differentiate depending on cytokine 
environment. Activation in the presence of cytokines will result in suppression or 
activation of genes responsible for driving CD4 T cell commitment to different lineages.  
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Among many factors, infected epithelial cells secrete transforming growth factor beta 
(TGF-β) and IL-10, which have been shown to impede early immune responses to 
influenza A infection (Denney et al. 2018; Williams et al. 2005). Furthermore, levels of 
TGF-β have been shown to significantly increase in aged mice, correlating with elevated 
numbers of Treg cells in the lungs after flu infection (Lefebvre and Masters et al. 2016). 
TGF-β is also a very well known inducer and stabilizer of FoxP3 expression in Treg cells 
(Marie et al. 2005). Deletion of the TGF-β receptor 1 on Treg cells in mice causes Treg 
defects in recruitment and suppressor functions in aged mice (Konkel et al. 2017). Treg 
cells exert suppressor functions that dampen inflammation and TH1 responses mediated 
in part by TGF-β secretion which reduces IFN-γ production in CD25- CD4+ T cells in a 
dose-dependent manner (Shen et al. 2013; Park et al. 2007). Tregs can also inhibit IL-2 
production, a necessary cytokine signal for CD4 T cell proliferation (Thornton et al. 1998, 
Shen et al. 2013).  
 
TGF-β in the tissue environment also inhibits the differentiation of TH2 cells by repressing 
Gata3 via Sox4 induction (Kuwahara et al. 2012). Moreover, IL-10 signaling through the 
IL-10 receptor on Treg cells also induces Stat3 activation which in turn represses TH17 
differentiation (Chaudhry et al. 2011). In addition, with significant IFN-γ in the tissue 
environment, however, Treg cells have been shown to upregulate the TH1 transcription 
factor Tbet and express CXCR3, a chemokine receptor important for TH1 migration, on 
their surface to allow for homeostasis and function in type I inflammatory conditions (Koch 
et al. 2009). While the major source of the TGF-β in aged lungs is still unclear, it is possible 
that it comes from multiple cell types, including epithelial cells and Treg CD4 T cells 
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themselves. The TGF-β presence greatly contributes to an environment that supports the 
expansion of Treg cells as opposed to other subsets with aging.  
 
CD4 T cells can differentiate into TH1 cells in the presence of IL-12 secreted by APCs in 
a Stat4-dependent manner and has been shown to be required for a strong TH1 
phenotype and endogenous IFN-γ production (Szabo et al. 2000; Athie-Morales et al. 
2004; Heufler et al. 1996). Exogenous IFN-γ is very important in the stabilization of TH1 
phenotype by mediating upregulation of the IL-18 and IL-12 receptor subunits in the 
presence of IL-4 (Smeltz et al. 2002). IL-27 in the environment is also key in the 
suppression of Gata-3, a TH2 transcription factor, further supporting the upregulation of 
Tbet and suppression of a TH2 phenotype in differentiating CD4 T cells (Lucas et al. 
2003). With age, however there is a shift after flu infection to more regulatory and type II 
responses, suggesting that without a strong TH1 inflammatory phenotype at the early 
stages of the adaptive immune response prolongs inflammation, elongates the kinetics of 
viral clearance, and lung damage over time, as shown in this thesis. Taken together, this 
shows the incredible influence cytokines have on CD4 T cell function and expression of 
subset-specific genes and surface molecules. 
 
A final CD4 T cell subset examined in this thesis is TFH cells. After priming by APCs and 
the presence of the IL-6 and IL-2, as well as ICOS–ICOS ligand stimulation, the BCL6 
gene is activated, initiating the TFH program (Tubo et al. 2013; Nurieva et al. 2009). 
CXCR5 is also upregulated while CCR7 is downregulated, allowing the cells to migrate 
to the T-B cell border within the lymph node follicle (Haynes et al. 2007). TFH generation 
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is also reinforced when in the presence of IL-21, which can be appreciated for its co-
stimulatory role and enhances expression of the IL-21 receptor (Vogelzang et al. 2008). 
TFH cells are critical for their helper roles in B cells producing high affinity neutralizing 
antibody. TFH cells in the lymph node secrete IL-4 and IL-21, which are important signals 
for B cells to induce class switch recombination and promote differentiation and survival 
of B cells and plasma cells (Paul et al. 1987; Yusuf et al. 2010; Ozaki et al. 2004).  
 
While the TFH population has been shown to increase with age, TFH in aged mice have 
impaired function and a reduced ability to help B cell antibody production (Lefebvre and 
Masters et al. 2016). TFH interactions with B cells are also hindered by disorganization of 
the segregated T-B cell zones within the lymph node (Lefebvre and Masters et al. 2016; 
Masters et al. 2019). Moreover, it has been shown that aged mice have a similar number 
of TFH cells in the lungs as compared to young mice during flu infection, however, their 
antibody production levels are significantly lower than young mice in serum (Lefebvre and 
Masters et al. 2016). With more IL-10 and IFN-γ in the aged environment, TFH – B cell 
interactions are impaired and it is also suggested that these aged TFH cells take on a more 
regulatory phenotype, which could contribute to the regulatory-like phenotype seen in 
aged mice, thus skewing age-related flu responses (Lefebvre and Masters et al. 2016). 
The above shows a very important link between humoral and cellular immunity and 
emphasizes why CD4 T cells are important to the flu response. It is crucial to understand 
how these subsets change with age in order to better understand the roles of cellular 
immunity to flu in aging populations.  
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Throughout this thesis, the early phase of flu infection is examined and Treg, TH1, and 
TFH populations are assessed in the mediastinal lymph node (MLN), lung, and spleens of 
aged mice. It is suggested here that the aged environment prevents the differentiation 
and expansion of TH1 cell populations and favors Treg differentiation early after the flu 
infection and is hypothesized here to be one of the main drivers of dysregulated CD4 T 
cell responses in aged lungs. TH1 cells have been shown to enhance recruitment of 
necessary inflammatory cells through IFN-γ and TNF-α secretion and to promote 
activation and proliferation of surrounding CD4 and CD8 T cells through IL-2 secretion 
(Bennett et al. 1997; Laidlaw et al. 2014). With reduced TH1 levels that occur with age, 
CD8 T cell help is diminished and TH2 and Treg subtypes predominate.  
 
Moreover, what is also important is having a balance between each of the subsets: TH1, 
TFH, Treg. While they each have their own functions, they are all important in the early 
CD4 T cell response to influenza in order to clear virus and mediate protection. Working 
in concert, Treg, TH1, and TFH CD4 T cells mediate helper responses and enhance flu 
responses. With aging, the balance of these cells is significantly affected and the cause 
of the reported changes in cytokine profiles after flu infection with aging remains largely 
unknown. One of the topics discussed further in this thesis is the attribution of the aged 
environment and senescence to the changes in age-related cytokine profiles and CD4 T 
cell differentiation and expansion after flu infection. Senescence has become a large 
exploration point in aging research, however it has never before been studied how 
senescence contributes to age-related changes seen in the context of viral infection.  
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CHAPTER SIX 
 
The Impact of the Aged Environment on CD4 T Cell Responses 
 
CD4 T cells are very responsive to their surrounding environment. Cues from chemokines 
and cytokines direct CD4 T cells in a multitude of ways and as such control flu responses 
in a tightly orchestrated manner. Many CD4 T cell-related changes and defects have been 
discovered with aging, as described earlier, however, through manipulation of the aged 
environment, compensation for these changes in CD4 T cell populations can be 
observed. This is particularly interesting when we consider therapeutically balancing and 
enhancing CD4 T cell responses in a way that overrides the signals received from the 
aged environment. For example, through in vitro studies using CD4 T cell receptor 
transgenic (TCR Tg) mice that were specific to pigeon cytochrome C antigen, it was 
shown that CD4 T cells produce significantly lower amounts of IL-2 and expand less when 
compared to CD4 TCR Tg cells from young mice (Haynes et al. 1999). Interestingly 
however, with exogenous IL-2 added during effector generation, the aged CD4 TCR Tg 
cell capacity to proliferate and differentiate was significantly restored when compared to 
young (Haynes et al. 1999; Haynes et al. 2004). 
 
Further ex vivo studies demonstrated that exogenous IL-2, in conjunction with additional 
inflammatory cytokines, TNF-α, IL-1, and IL-6, enhanced endogenous aged T cell IL-2 
production restoring levels to those seen in young mice and also increased NF-κB 
expression, which plays an important role in many aspects of CD4 T cell differentiation 
(Haynes et al. 2004; Corn et al. 2005; Aronica et al. 1999). It has been shown that with 
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age the number of naïve CD4 T cells in the periphery decreases and there is a shift in the 
CD4 T cell compartment to a predominately memory phenotype. In studies examining the 
mechanisms of naïve CD4 T cell homeostasis, it was found that naïve CD4 T cells 
maintained their IL-7 receptor (IL-7R) expression, which is important for survival in the 
periphery, indicating that this IL-7-IL-7R signaling could be the cause of environmentally 
driven defects (Becklund et al. 2016). Reductions in the naïve CD4 survival was largely 
due to defects found in the secondary lymphoid tissue and in vivo treatment with IL-7/anti-
IL7 monoclonal antibody complex, restored naïve cell survival (Becklund et al. 2016; 
Boyman et al. 2008). Secondary lymphoid tissues have a reduction in the levels of CCL19 
and CCL21, both of which are CCR7 ligands on high endothelial venules (HEVs) and 
fibroblastic reticular cells (FRCs) that are critical for T cell migration into lymphoid tissues 
(Becklund et al. 2016; Masters et al. 2018; Mueller et al. 2007). Another chemokine, 
CXCL13, secreted by follicular dendritic cells and important for migration of B cells with 
the lymphoid tissues, was also reduced with age (Becklund et al. 2016).  
 
To address the possibility of cell intrinsic defects in aged CD4 T cell populations, adoptive 
transfer studies examining the impact of the aged microenvironment on young donor 
CD4 TCR Tg cells specific to ovalbumin peptide (OT-II CD4 T cells) have also been 
performed (Lefebvre et al. 2012). Interestingly, transferred young OT-II CD4 T cells into 
aged hosts displayed a reduction in recruitment and proliferation of OT-II cells in the 
spleens of aged mice (Lefebvre et al. 2012). As seen in previous studies, there was a 
reduction in CCL19, CCL21, and CXCL13 in aged spleens (Lefebvre et al. 2012). In 
addition, there was also reduced differentiation to a TFH phenotype in aged hosts when 
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compared to young (Lefebvre et al. 2012). These results indicate that the aged 
environment has a profound impact on the response of young CD4 T cells to in vivo. 
There was also a greater proportion of young OT-II CD4 T cells transferred into aged 
hosts that began to express the Treg-associated transcription factor Foxp3 when 
compared to those same OT-II T cells transferred into young hosts (Lefebvre et al. 2016). 
Consistent with previous reports of age-associated environmental and cellular changes, 
not only is there a reduced response to antigenic stimulation in the aged host, there is 
active induction of a regulatory-like and memory phenotype in the young donor T cells 
(Lefebvre et al. 2016; Linton et al. 2005).  
 
Taken together, these studies show that there is a very large contribution of the aged 
environment on the differentiation, function, and expansion of CD4 T cells. Although these 
previous studies have explored CD4 T cell migration and responses in aging in the 
lymphoid tissues like the lymph nodes and spleens, much less is known about non-
lymphoid tissues and how CD4 T cells respond in the lungs after infection. Moreover, it 
has been shown that chemokine responses, namely CXCL13, CCL19, CCL21, are 
antigen dependent (Mueller et al. 2007). Using flu vaccination and priming of CD4 T cells 
with flu peptides as model systems, the responses were examined leading to a new 
hypothesis for the cause of age-related declines in CD4 T cells. An important change in 
aging, which has never before been addressed in the context of T cells in responses to 
infection, is senescence. This is an inevitable part of aging and has been shown to have 
many implications in chronic age-related diseases. One of the hallmarks of senescence 
is the inflammatory signals secreted by senescent cells. With the direct impact cytokines, 
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chemokines, and other secreted factors have on CD4 T cell signaling, it is important to 
address the effects of the senescent environment on CD4 T cells.  
 
 
The Senescent Cell 
 
Cellular senescence is characterized by irreversible growth arrest that occurs when cells 
experience potentially oncogenic insults. They are unable to go through apoptotic 
pathways of self-elimination and rely on immune cells for clearance (Baker et al. 2011). 
Most importantly, the number of senescent cells increases with chronological aging, as 
accumulation surpasses the rate of elimination of senescent cells by phagocytic cells 
(Baker et al. 2011). Senescence plays an important part in regulating cell cycle, which in 
turn, has an effect on DNA synthesis and division of mitotic cells; processes important to 
maintain the genetic integrity of the cell. These processes prevent mutations from 
accruing, which often manifest in the form of diseases and cancer. Progression through 
the cell cycles is dependent on passing four stages; G1, S (DNA synthesis), G2, and M 
(mitosis) phases.  
 
The primary G1/S checkpoint requires the formation of cyclin-dependent kinase CDK4/6-
cyclin D complexes (Sherr et al. 1999; Neganova et al. 2008). They phosphorylate cell 
cycle/tumor suppressor retinoblastoma protein (pRb) which then releases the E2F 
transcription factors that transcribe genes required for DNA replication and further cell 
cycle progression (Giacinti et al. 2006; Bockstaele et al. 2009; Coleman et al. 1997). This 
checkpoint ensures that if the cell is not ready to undergo division, pRb will stay 
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unphosphorylated and prevent the cell cycle from continuing. A senescent cell, however, 
remains in a state of irreversible cell cycle arrest (Campisi et al. 2007; Sharpless et al. 
2015), which could be due to a variety of stress stimuli including replicative exhaustion, 
telomere shortening, DNA damage and/or active oncogenes (Campisi et al. 2007; 
Sharpless et al. 2015).  
 
To prevent damaged/stressed cells from replicating, CDK inhibitors (CDKI)s, including 
p16INK4a, p21Cip1/Waf1, p27Kip1, and p53 control cell cycle progression by inhibiting 
phosphorylation of pRb. Although these proteins are all important in regulating this 
process and play a role in senescence, p16 in particular has been shown, in particular, to 
be involved in not only the halting of cell cycle, but also the maintenance of cellular 
senescence (Stein et al. 1999). p16 binds to CDK4/6 proteins to inhibit their interaction 
with cyclin D, thus resulting in pRb hypophosphorylation. p16 is a relatively stable protein 
that is regulated by transcriptional control, depending on the presence or absence of 
stress signals (Kotake et al. 2015). In various cancers, including carcinomas, melanomas, 
and lymphomas, however, the p16 gene is often mutated or deleted, and contributes to 
the loss of cell cycle regulation (Ligget and Sidransky 1998).  
 
Senescent cells display characteristics and phenotypes that when examined in 
conjunction make them distinguishable from normally replicating or quiescent cells. In 
addition to being non-replicative (Ki67-) and unable to incorporate nucleotide analogs 
(BrdU-), these cells appear morphologically bigger (Becker et al. 2013; De Cecco et al. 
2011). They can have vacuolated cytoplasm as well as increased levels of proteins in 
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their nucleus and cytoplasm (De Cecco et al. 2011). Lysosomes expand in senescent 
cells leading to an increase in lysosomal beta-galactosidase (β-gal) (Dimri et al. 1995). 
These cells also show increased DNA damage foci and condensed heterochromatin 
regions, shown using γH2AX and H3K9meth antibodies, respectively (Narita et al. 2003; 
Adams 2007; Becker et al. 2013). Senescent cells also express p16 in later stages of 
senescence and has been widely used as a marker in human and mouse in vitro and in 
vivo models (Becker et al. 2013). 
 
Although senescence leads to irreversible cell cycle arrest, senescent cells stay 
metabolically active and display many cellular changes. Senescent cells can become 
resistant to apoptosis, have protein aggregation in endoplasmic reticulum, defective 
mitochondria, and have nonfunctional lysosomes (Kuilman et al. 2010; Rayess et al. 
2011). In addition, they express the senescence associated secretory phenotype (SASP), 
which has been described recently as the ability of these cells to secrete many growth 
factors, cytokines and chemokines, which attract immune cells, such as macrophages 
and natural killer cells, to aid in elimination (Young et al. 2009; Coppe et al. 2008; 
Parrinello et al. 2005). It has been shown, however, that if senescent cells are not 
effectively cleared, they can accumulate and chronically secrete inflammatory cytokines, 
like IL-6 and IL-8, which can negatively affect self-elimination (Coppe et al. 2008; Wiley 
et al. 2017). This accrual of senescent cells then has further deleterious effects on 
neighboring cells and tissues (Young et al. 2009; Coppe et al. 2008; Parrinello et al. 
2005). This accrual ultimately creates a microenvironment caused by senescent cells 
within the tissue that has been shown to significantly contribute to the aged tissue 
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environment. Even further, it has been shown using other transplantation models, that 
transplantation of senescent cells into the knee joints can induce an osteoarthritis-like 
phenotype in healthy in young mice. Interestingly, senescent cells have a major impact 
on the surrounding tissue, however, they only represent a small percentage of total cells 
(Biran et al. 2017). Although senescence can have both negative and positive roles with 
aging, the effects on the immune system are largely unknown. In order to understand 
these effects, models of senescence have been developed to further examine and define 
what is happening. Although not perfect, these systems serve as the first attempts to 
identify, isolate, and eliminate senescent cells in order to understand mechanisms of 
senescence with aging.  
 
 
Models of Senescence 
 
Studies performed using mouse models created by the Kirkland and Campisi laboratories 
have shown senescent cells accumulate with age and that following their ablation, mice 
can be rejuvenated and reversal of some age associated diseases can occur (Baker et 
al. 2011; Demaria et al. 2014). It has also been shown that p53 can delay functional 
decline in BubR1 mice through a p21-dependent pathway since it can inhibit p16 
activation in progenitor cells of fat and skeletal muscle, providing the groundwork for yet 
another potential model of senescence control in mice (Baker et al. 2013). Both the 
Kirkland and Campisi senescent mouse models target the p16IK4a gene.  
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The Campisi mouse model in particular, used in this thesis work and as previously 
described (Demaria et al. 2014), is unique, allowing for the ablation of p16INK4a 
expressing senescent cells selectively by injection of ganciclovir (GCV). The laboratory 
used a 3MR (trimodality reporter) approach, which uses the functional domains of a 
synthetic Renilla luciferase (LUC), monomeric red fluorescent protein (mRFP), and a 
truncated HSV-1 thymidine kinase (HSV-TK) under the control of the senescence-
associated p16INK4a promoter. They engineered a bacterial artificial chromosome (BAC) 
to contain ~50kb of the murine p16INK4a locus so it drives the 3MR expression. The 
p16INK4a coding sequence and neighboring p19-ARF (important for regulation of cell 
cycle/tumor suppressor gene p53) (Park and Vogelstein 2003) were then inactivated in 
the BAC. Using the C57BL/6 mouse as the background strain, the transgenic mouse 
model was created by selecting mice that genetically expressed one integrated copy of 
the p16-3MR fusion proteins. LUC allows for detection of p16-3MR cells by luminescence, 
while mRFP can be used to detect the senescent cells by fluorescence using microscopy 
or flow cytometry. Ganciclovir has a high affinity for HSV-TK (but not cellular TK), and 
when bound converts ganciclovir into a mitochondrial DNA chain terminator in senescent 
cells leading to fragmentation of mitochondrial DNA and apoptosis (Demaria et al. 2014; 
Laberge et al. 2013).  
 
The Campisi lab has shown through the use of this model, that in aged mice, senescent 
cells are important for wound healing, although they also are responsible for many age-
related pathologies (Demaria et al. 2014). This mouse model, however, has not been 
used to specifically study the effects of senescent cells on the aged immune system, in 
particular, the functions of CD4 cells. In this thesis, the Campisi p16-3MR mouse model 
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is used in the first ever examinations of the direct effect of senescence on CD4 T cell 
functions. Models of senescence are not perfect, especially considering all cells that 
express p16 may not be fully senescent and there is research to suggest that some cells 
expressing low levels of p16 can exit the senescence program in tumor cell populations 
(Debacq-Chainiaux et al. 2009).  
 
Cell and tissue type-specific targeting of senescent cells is not possible as of yet, although 
mouse models of cell and tissue type-specific targeted senescence are being developed. 
Nonetheless, using these models in this thesis in other ways, provide the first clues into 
the function and impact this small population of cells has on an entire tissue, especially 
in the context of infection. As shown before in wound healing studies (Demaria et al. 
2014), this small percentage of cells makes a significant difference in tissue repair. It is 
clear to see, even with caveats that this is a significantly impactful model. The limitations 
of these models are taken into account for this thesis work, however it does still lay the 
groundwork for examining the contribution of senescent cells in general to an infection 
response. 
 
SASP and CD4 T Cells  
 
Factors secreted by senescent cells can have a direct impact on surrounding cells driving 
dysfunction and age-related pathologies. As discussed earlier, many of these factors are 
cytokines that also drive TH2, memory, and Treg CD4 T cell differentiation (Lefebvre et 
al. 2012). Even more interesting, is that TGF-β secreted by epithelial cells, other 
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fibroblastic-type cells, and immune cells such as macrophages in the lung is one of the 
main drivers of senescence and can reinforce senescent cell phenotypes (Reimann et al. 
2010; van Riggelen et al. 2010; Rapisarda et al. 2017).  Not only is exogenous TGF-β 
impacting senescent cells, but TGF-β production has also been shown to be upregulated 
in human fibroblasts that have become senescent (Rapisarda et al. 2017). This suggests 
that TGF-β may play a very large role in not only senescence, but also the senescence 
microenvironment in tissues that that will have an effect on CD4 T cell polarization, 
especially to a more regulatory phenotype.  
 
Senescent cells accumulating in tissues will create their own microenvironment and the 
pro-inflammatory cytokines, chemokines, and extracellular matrix proteases they secrete 
are collectively termed the senescence-associated secretory phenotype (SASP). The 
SASP entails the secretion of a myriad of cytokines (IL-6, IL-7, IL-1 alpha & beta, IL-13, 
IL-15), angiogenic and growth factors (amphiregulin, EGF, HGF KGF, VEGF, IGF) and 
proteases (MMP, TIMP 1 & 2, PAI-1) (Coppe et al. 2010; Ghosh and Capell 2016). If 
senescent cells are not effectively cleared, they can accumulate and chronically secrete 
inflammatory cytokines, such as IL-6 and IL-8 (or IL-8 homologs KC, MIP-2 and LIX in 
mice), which can negatively affect their own clearance. This perpetuates a cycle of 
senescence and drives more tissue dysfunction and cellular decrements in the context of 
immunity.	
    
The impact of senescent cells on immune cell function in this context has not yet been 
studied. In this thesis, the effects of senescent cells on CD4 T cell differentiation and 
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expansion in tissues following flu infection will be examined in preliminary studies for the 
first time. It is possible that senescent cells alter CD4 T cell helper subset differentiation 
and effector function. It is also possible that influenza can be an inducer of senescence 
in the lungs of aged mice.  
 
 
Senolytic Drugs as a Mechanism of Preventing Age-Associated Disease 
 
 
Senescence-eliminating mouse models are very useful in tracking elimination and accrual 
within tissues, however, there are other methods of eliminating senescent cells using 
pharmacological interventions in non-genetically modified mice called senolytic drugs 
(Kirkland et al. 2015). Although very new, with the first use of senolytic drugs only being 
described in 2015, they have become an additional way to study the effects of 
senescence in vitro and in vivo and more drugs are rapidly being discovered and/or 
repurposed as senolytics (Zhu et al. 2015; Kirkland et al. 2017). Some have been 
identified as better senolytics in vivo in particular and display overlap in targeting several 
senescent cell anti-apoptotic pathways (SCAP) to induce apoptosis in senescent, but not 
quiescent or proliferating cells (Wang et al. 1995; Fuhrmann-Stroissnigg et al. 2017; 
Chang et al. 2016; Baar et al. 2017; Zhu et al. 2016). Two in particular are used in tandem 
and have been shown in vitro and in vivo to be effective at senescence cell elimination: 
dasatinib and quercetin (D+Q) (Zhu et al. 2015; Triantafyllou et al. 2008). It is a possibility, 
however, that because different cell types have different origins, that targeting one protein 
in the SCAP pathway may not be effective in all cell types. This poses a caveat in 
treatment with senolytic drugs and highlights the importance of choosing the most 
effective senolytic drug for the tissue being examined. Using both D+Q may be a way 
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around this caveat in vivo as the drugs together can target multiple SCAP pathway 
proteins (Kirkland et al. 2017).  
 
Dasatinib is a tyrosine kinase inhibitor and can be appreciated for its wide use in treatment 
of cancers (Montero et al. 2011). In a recent report, dasatinib showed very positive effects 
on long term use for therapy in patients with chronic myeloid leukemia (Maiti et al. 2020). 
It induced a fast cellular regeneration response and showed excellent survival in the 
patients, making it an effective therapeutic and candidate as a senolytic (Maiti et al. 2020). 
It is also a known to interfere with ephrine (Eph) receptor-dependent inhibition of 
apoptosis (Xi et al. 2012; Chang et al. 2008). Upon DNA damage, EphB1 is involved in 
signaling p53 and p21 tumor suppressor genes and cell cycle inhibitory genes (Kampen 
et al. 2015; Soto-Gamez and Demaria 2017). When the Eph receptor is blocked by 
dasatinib, cells undergo apoptosis, potentially through a caspase-dependent pathway 
(Mpakou et al. 2013). In one of the first studies to examine the senolytic capacity of 
dasatinib, it was observed that it preferentially reduced the viability and caused cell death 
of human preadipocytes in vitro in a dose-dependent manner, but had little effect on 
human umbilical vein endothelial cell (HUVEC) cultures (Zhu et al. 2015). Quercetin was 
shown to induce apoptosis in the HUVECs but is much less effective in killing senescent 
preadipocytes like dasatinib (Zhu et al. 2015). Quercetin is a flavanol that has many 
implications in the PI3K/Akt (Zhu et al. 2015), p53 (Zhu et al. 2015), as well as HIF-1α 
(Triantafyllou et al. 2008) pathways. It can also inhibit the mTOR pathways and has been 
shown to inhibit cell growth in cancer cells (Olave et al. 2010; Bruing 2013). When used 
in vivo, D+Q showed similar effects in eliminating senescent cells, proving the potency of 
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this senolytic drug combination (Zhu et al. 2015). Taken together, using a combination of 
D+Q, senescence can be eliminated from a number of different cell types and, for the first 
time, is used in this thesis to examine the effects of senescence on CD4 T cell effector 
subsets in lung tissue of flu infected aged mice.  
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CHAPTER SEVEN 
 
 
Goal of Thesis 
 
 
 
The primary goal of this dissertation is to expand our understanding of how aging impacts 
the immune response to influenza infection, with emphasis on CD4 T cell subsets. The 
hypothesis of this thesis is that the aged environment alters CD4 T cell differentiation into 
appropriate subset populations that are crucial to orchestrating an effective cellular-
mediated flu response.  
 
 
In chapter eight of this thesis “Examining the Decrements in Flu Responses with Age,” 
we elucidate how age is a significant factor in preventing effective anti-flu responses and 
control of inflammation. We examine how vaccination affects early stages of the flu 
response and if passive treatment with monoclonal antibody will aid in the recovery of 
aged mice from flu. In addition, we study how CD4 T cell subsets after flu infection in aged 
mice display altered subset differentiation when compared to young mice. This was 
examined because of the data indicating that antibody is not sufficient to protect aged 
mice from the flu and the fact that inflammatory cytokines are important in polarizing CD4 
T cells to become one subset over another. Cellular mediated protection, in the context 
of CD4 T cells is very important in enhancing immune mediated defenses against flu. 
Each subset of CD4 T cells maintains its own specialized function, all of which work 
together at varying times during the response to flu.  
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In chapter nine of this thesis “Examining the Effects of Vaccination on Aged CD4 T Cell,” 
we use vaccination as a method of priming CD4 T cells to respond to flu infection. We 
study how vaccination with a TH1 polarizing adjuvant AddaVax regulates CD4 T cell 
differentiation in the lymph nodes and spleen, and expansion in the lungs following 
subsequent infection. In addition, the differences in inflammatory mediators between 
vaccinated and unvaccinated mice are compared. We also explore the possibility that 
TGF-β could play a role in vaccination-mediated protection and CD4 T cell subset 
regulation.  
 
In chapter ten “Examination of Senescence in Aged Mice,” preliminary studies are 
performed to assess the contribution of senescence to CD4 T cell subsets in the lung. By 
eliminating senescent cells using a senolytic drug D+Q, we can begin to tease apart the 
impact senescent cells have on the direction of CD4 T cell differentiation and expansion. 
In addition, senescence is also examined using the p16-3MR mouse model for detection 
of p16+ senescent cells in the lung. 
 
 
The work described in this thesis advances our knowledge of CD4 T cell subsets and 
their differentiation into specialized effector populations under varying conditions in the 
aged environment. In addition, this work uses novel model systems, namely the use of 
senolytics and the p16-3MR model of senescence to examine not only its effect on the 
aged environment, but also on CD4 T cell subset differentiation. Although the 
senescence-related work in this thesis is brief, it is still the first work to use these models 
in the context of aging, flu infection, and CD4 T cells.   
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RESULTS 
 
CHAPTER EIGHT 
 
Examining the Decrements in Flu Responses with Age 
 
Aged mice display increased lung damage and lingering inflammation after flu infection 
 
As described earlier, aged mice are particularly susceptible and succumb to flu infection 
because of decrements in the immune system with age. In order to investigate the impact 
aging has on the kinetics of the immune response during influenza infection, young and 
aged C57BL/6 mice were intranasally infected with PR8 influenza. Lung tissue and 
bronchiolar lavage (BAL) fluid and cells were harvested at various time points up to 12 
days post-infection (dpi). Both young and aged groups reached a similar peak of viral load 
between days 3 to 6 of infection. Virus levels in both groups were decreasing by day 9 
but the aged groups still exhibited significantly higher copy numbers at 9 and 12 dpi 
(Figure 2A). While this age-related difference appears subtle at these later time points, 
the data are expressed in log10 copy numbers of the influenza acid polymerase (PA) gene 
(Jelley-Gibbs et al. 2007). Thus, the differences between the young and aged groups are 
substantial and the aged mice have delayed clearance of influenza virus in the lung tissue. 
The delay in viral clearance in the aged mice could also cause increased lung damage 
and inflammation. Quantifying albumin levels BAL is a good measure of lung damage 
(Bhan et al. 2015), thus this was examined this during the course of infection (Figure 2B). 
Interestingly, young mice had slightly elevated levels of albumin in the BAL, which 
plateaued between 6 and 12 dpi. Aged mice also had elevated levels of albumin, which 
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continued to increase from 6 to 12 dpi in comparison to the young mice at each respective 
time point. This indicates that there is ongoing lung damage that is not resolving in the 
aged lungs.  
 
The BAL fluid was also examined for inflammatory cytokines that are critical for viral 
clearance (Figure 2C). The levels of G-CSF were quantified, which promotes the 
accumulation of granulocytes and facilitates viral clearance (Hermesh et al. 2012), IL-6, 
which is vitally important for neutrophil survival and viral clearance (Dienz et al. 2012), 
and IL-1α, which mediates lung pathology while also enhancing survival via activation of 
the adaptive immune response and clearance of the virus (Schmitz et al. 2005). Young 
mice had increased levels of inflammatory cytokines G-CSF, IL-6, and IL-1α, which 
peaked at 6 dpi and then returned to baseline by day 12 as the infection was resolving. 
Aged mice, however, had significantly higher levels of each cytokine on days 9 and 12 
without a return to baseline levels that was seen with the young groups. Additional 
cytokines and chemokines also followed a similar pattern of being elevated in the aged 
groups, especially at later time points (Figure 3A), while others, such as the effector 
cytokines IFN-γ and IL-10, were delayed in the aged (Figure 3B) and some chemokines 
important for recruiting innate and adaptive immune cells to the lungs during infection 
were found to be higher in the young groups (Figure 3C). Taken together, these results 
show that, along with a delay in the clearance of influenza infection and generation of 
effector cytokines in the aged mice, there is also significantly increased lung damage and 
lingering inflammatory cytokines and chemokines, possibly in response to the lingering 
virus in the aged lungs.  
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In order to determine if age-related differences in infiltrating cells could have been 
contributing to this dramatic increase in inflammatory cytokines and chemokines, cells in 
the BAL were examined. Interestingly, there were few significant differences between 
young and aged groups with regards to the percentages of specific cell types in the BAL 
population, with slightly more neutrophils in the young and slightly more macrophages in 
the aged at 3 dpi (Figure 2D). Importantly, there were no significant differences in cell 
numbers between the young and aged groups throughout the infection (Figure 2E). Thus, 
it is unlikely that the ongoing inflammation seen in the aged lungs is due to excessive 
cellular infiltrate but might be attributed to age-related changes in the quantities of 
cytokines produced per cell following flu. 
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Figure 2. Lingering inflammatory cytokines and lung damage in aged lungs during influenza 
infection. Young (2-3 mos.) and aged (19-22 mos.) C57BL/6 mice were infected intranasally with 400 
EID50 of PR8 influenza. On 1, 3, 6, 9 and 12 dpi, BAL fluid and cells and lung tissue was harvested; mRNA 
was isolated from lung tissue. A) The total number of copies of influenza PA was determined by real-time 
PCR of mRNA from lung tissue. B) Albumin in the BAL was determined by ELISA and C) Cytokines in the 
BAL were determined by multiplex analysis. The percentage D) and number E) of macrophages, neutrophils 
and lymphocytes in the BAL was determined by differential staining. For all experiments, data shown is 
combined from 2 independent experiments and each symbol represents a single animal; line shows the 
mean. *p < 0.05 by 2-way ANOVA with Bonferroni posthoc correction. 
Oncotarget33583www.impactj urnals.com/oncotarget
Figure 1: Lingering inflammatory cytokines and lung damage in aged lungs during influenza infection. Young (2-3 mos.) 
and aged (19-22 mos.) C57BL/6 ice were infected intranasally with 400 EID50 of PR8 influenza. On 1, 3, 6, 9 an  12 dpi, BAL fluid and 
cells and lung tissue was harvested; mRNA was isolated from lung tissue. A. The total number of copi s of influenz  PA was determined by 
real-time PCR of mRNA from lung tissue. B. Albumin in the BAL was determined by ELISA and C. Cytokines in the BAL were determined 
by multiplex analysis. The percentage D. and number E. of macrophages, neutrophils and lymphocytes in the BAL was determined by 
differential staining. For all experiments, data shown is combined from 2 independent experiments and each symbol represents a single 
animal; line shows the mean. *p < 0.05 by 2 way ANOVA with Bonferroni posthoc correction.
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Figure 3. Cytokines and chemokines that are differently secreted in aged and young mice after flu 
infection. Young (2-3 mos.) and aged (19-22 mos.) C57BL/6 mice were infected intranasally with 400 
EID50 of PR8 influenza. On 1, 3, 6, 9 and 12 dpi, BAL fluid and cells and lung tissue was harvested. A) 
Cytokines and chemokines in the BAL that are significantly upregulated in aged lungs compared to young. 
B) Cytokines and chemokines that are delayed in aged BAL compared to young, important for regulating 
viral clearance and recovery. C) Cytokines and chemokines in the BAL were determined by multiplex 
analysis. For all experiments, data shown is combined from 2 independent experiments and each symbol 
represents a single animal; line shows the mean. *p < 0.05 by 2-way ANOVA with Bonferroni posthoc 
correction. 
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Effect of NP Vaccination on Aged Responses to Influenza 5 dpi 
 
Previous studies have shown that one of the most effective ways to reduce inflammatory 
cytokines and chemokines in the lungs during influenza infection is by priming immune 
cells using vaccination (Haynes et al. 2012; Lanthier et al. 2011). Vaccination with 
influenza NP is a useful approach since this recombinant protein is easy to generate and 
it induces robust heterosubtypic immunity (Carragher et al. 2008), thereby overcoming 
two major deficiencies of the seasonal inactivated whole virus vaccines. The effects of 
vaccination with NP in aged mice is not yet fully understood and as a result, the early time 
point of five dpi was chosen to examine the acute flu responses in aged mice. It is very 
important to understand the kinetics of flu responses with aging, especially due to the fact 
that the flu response without vaccination is delayed in aged mice.   
 
Young and aged mice were vaccinated with recombinant NP or PBS as a control and 
then infected with PR8 influenza. Weight loss and survival were then monitored. NP 
vaccination prevented weight loss in young mice following influenza infection, however 
there was no significant difference in weight loss between vaccinated and unvaccinated 
aged groups (Figure 4A). Importantly, NP vaccination did confer protection from mortality 
in the aged cohort, with 100% survival in the vaccinated group compared to 30 percent in 
the unvaccinated aged group (Figure 4B). Thus, while vaccination of the aged mice does 
not protect from influenza-induced weight loss, it does rescue aged mice from death. It is 
possible that vaccination acts through mechanisms protecting aged mice from mortality, 
other than weight loss, and could be mediating protection through other cell-mediated 
ways.  
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Figure 4. Protection from influenza by NP vaccination. Young (2-3 mos.) and aged (19-22 mos.) 
C57BL/6 mice were vaccinated with NP or PBS on days -31 and -21. On day 0, they were infected 
intranasally with 400 EID50 of PR8 influenza. A) Weight loss and B) survival were monitored following 
infection.  Data shown is combined from 2 independent experiments with a total of 8 to 10 mice per group. 
*p < 0.05 by Student’s t-test comparing vaccinated and control groups; **p < 0.05 by Log rank test. 
 
 
Young and aged mice vaccinated with NP or PBS were challenged with PR8 influenza 
and examined 5 dpi since this is the beginning of the flu response in both vaccinated and 
flu infected mice. Neither young nor aged NP vaccinated/infected (NP/PR8) mice had a 
significant reduction of virus in the lungs when compared to the PBS-vaccinated control 
groups (PBS/PR8) (Figure 5A). NP-vaccinated aged mice did, however, produce 
significantly higher amounts of anti-NP IgG serum antibodies when compared to controls 
(Figure 5B). Although higher than unvaccinated aged mice, the levels of antibody 
quantified were still was significantly lower than the amount of antibody produced by the 
vaccinated young mice. Furthermore, NP vaccination of young, but not aged mice, also 
reduced the level of albumin in the BAL when compared to the PBS control groups, 
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Figure 2: Protection from influenza and secondary bacterial infection by NP vaccination. Young (2-3 mos.) and aged (19-22 
mos.) C57BL/6 mice were va cinated with NP or PBS on days -31 a d -21. On day 0, they were infected intranasally with 400 EID50 of PR8 
influenza. A. Weight loss and B. survival were monitored following infection. C. On day 0, NP (right graph) or PBS (left graph) vaccinated 
young and aged mice were infected intranasally with 400 EID50 of PR8 influenza and then 5 dpi, infected with 250 CFU of Streptococcus 
pneumoniae and survival was monitored. Data shown is combined from 2 independent experiments with a total of 8 to 10 mice per group. 
*p < 0.05 by Student’s t test comparing vaccinated and control groups; **p < 0.05 by Log rank test.
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indicating that lung damage was also reduced in the young, but not aged lungs (Figure 
5C). 
 
Because this is an early time point post infection, inflammatory cytokines necessary for 
early stage responses like G-CSF, IL-6 and IL-1α in BAL following flu infection were 
compared between young and aged mice (Figure 5D). The levels of these cytokines in 
BAL from naïve uninfected young and aged mice is shown in the “none” groups. In young 
NP vaccinated and infected mice (NP/PR8), levels of these cytokines were reduced 
significantly compared to PBS/PR8 control group, which was vaccinated with PBS and 
then received influenza infection. In contrast, aged vaccinated and infected mice 
(NP/PR8) showed no significant reduction in these cytokines when compared to the 
PBS/PR8 control group. Other cytokines and chemokines responsible for mediating 
inflammation and recruitment of inflammatory cells into the lung also exhibited a similar 
pattern of expression in young and aged groups and could indicate that there is a delayed 
inflammation, even in vaccinated aged mice (Figure 6). Cells from the BAL fluid in each 
of these groups showed that NP vaccination of both young and aged mice prior to 
influenza infection resulted in an enhanced percentage of neutrophils when compared to 
the PBS/PR8 control groups (Figure 5E). Interestingly however, despite not having 
significantly more inflammatory cytokine secretion in the BAL (Figure 5D and Figure 6), 
vaccinated aged mice have a significantly lower percentage of macrophages and 
lymphocytes (Figure 5E). This could be an indication that the source of inflammation in 
aged mice, is not coming from immune cells, but rather from the lung tissue itself. While 
NP vaccination generates a significant amount of NP-specific IgG in aged mice and 
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protects from flu induced-death, it has no impact on viral load, BAL cytokines and 
chemokines, or albumin levels at early time points post flu infection. Taken together, it is 
possible that seeing benefits of priming in aged mice after flu, may only be observed in 
later time points post infection. Vaccination does not seem to effectively recover the 
decrements of aged responses as compared to young at this stage of infection in this 
model.  
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Figure 5. NP vaccination reduces lung inflammatory mediators and damage in influenza infected 
young, but not aged mice. Young [Y] (2-3 mos.) and aged [A] (19-22 mos.) C57BL/6 mice were vaccinated 
with NP or PBS on days -31 and -21. On day 0, they were infected intranasally with 400 EID50 of PR8 
influenza. On 5 dpi, A. lungs were harvested and mRNA was isolated to quantitate influenza PA by real-
time PCR. B. Anti-NP IgG titers in serum were determined by ELISA. Albumin C. and cytokines D. in the 
BAL were determined by ELISA and multiplex analysis, respectively. E. The percentage of macrophages, 
neutrophils and lymphocytes in the BAL was determined by differential staining. Groups labeled “none” 
represent BAL harvested from young or aged naive mice. Data shown is combined from 2 independent 
experiments and each symbol represents a single animal; line shows the mean. *p < 0.05 by 2 way ANOVA 
for A, B, C or 3 way ANOVA for D and E with Bonferroni posthoc correction. 
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it has no impact on viral load, BAL cytokines and 
chemokines or albumin levels. 
The role of antibody
Since the aged mice do produce a significant 
amount of anti-NP IgG, we next sought to determine 
if the protective effect (survival from infection) of NP 
vaccination could be attributable to this antibody. To 
do this, we employed adoptive transfer of a NP-specific 
monoclonal antibody (mAb). We chose this approach 
since we have previously shown that this mAb protects 
young mice from secondary bacterial infection following 
influenza and reduces inflammatory mediators in the lungs 
of young influenza infected mice [18]. The NP mAb or 
Figure 3: NP vaccination reduces lung inflammatory mediators and damage in influenza infected young but not aged 
mice. Young [Y] (2-3 mos.) and aged [A] (19-22 mos.) C57BL/6 mice were vaccinated with NP or PBS on days -31 and -21. On day 0, 
they were infected intranasally with 400 EID50 of PR8 influenza. On 5 dpi, A. lungs were harvested and mRNA was isolated to quantitate 
influenza PA by real-time PCR. B. Anti-NP IgG titers in serum were determined by ELISA. Albumin C. and cytokines D. in the BAL were 
determined by ELISA and multiplex analysis, respectively. E. The percentage of macrophages, neutrophils and lymphocytes in the BAL 
was determined by differential staining. Groups labeled “none” represent BAL harvested from young or aged naive mice. Data shown is 
combined from 2 independent experiments and each symbol represents a single animal; line shows the mean. *p < 0.05 by 2 way ANOVA 
for A, B, C or 3 way ANOVA for D and E with Bonferroni posthoc correction. 
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Figure 6. Cytokine and chemokine kinetics in young and aged mice following flu vaccination and 
subsequent infection. Young [Y] (2-3 mos.) and aged [A] (19-22 mos.) C57BL/6 mice were vaccinated 
with NP or PBS on days -31 and -21. On day 0, they were infected intranasally with 400 EID50 of PR8 
influenza. On 5 dpi, cytokines in the BAL were determined by multiplex analysis. Groups labeled “none” 
represent BAL harvested from young or aged naive mice. Data shown is combined from 2 independent 
experiments and each symbol represents a single animal; line shows the mean. *p < 0.05 by 3-way ANOVA 
with Bonferroni posthoc correction. 
 
 
Assessing the Protective Effect of Monoclonal Antibody Treatment in Flu Infection 
 
Since the aged mice do produce a significant amount of anti-NP IgG when compared to 
the unvaccinated group, the protective effect (survival from infection) of NP vaccination 
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being attributed to NP antibody was examined. To do this, adoptive transfer of an NP-
specific monoclonal antibody (mAb) was given to mice prior to and on the day of flu 
infection. This approach was chosen since it has been previously shown that NP mAb 
protects young mice from secondary bacterial infection following flu and reduces 
inflammatory mediators in the lungs of young influenza infected mice (Haynes et al. 
2012). The NP mAb or isotype control was administered on days -1 and 0 of flu challenge. 
Young mice receiving the NP mAb were protected from weight loss during flu infection, 
which could be due to having an intact immune system, while aged mice were not 
protected (Figure 7A). Importantly, however, aged mice that received the NP mAb were 
protected from death due to flu infection (Figure 7B), much like those vaccinated with NP 
protein (Figure 5B). Treatment with the NP mAb had no impact on the amount of virus in 
young or aged groups at this time point, which was expected as flu virus takes about 9 
days to clear without vaccination (Figure 2A and Figure 7C). In contrast, treatment of 
young mice with the NP mAb did significantly reduce the levels of BAL cytokines and 
chemokines but had no effect in the aged mice. (Figure 7D). Thus, in the aged groups, 
survival from influenza-induced weight loss and reduction in lung inflammation seem to 
be mediated separately, with Ab involved in survival, but not in reducing lung 
inflammation.  
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Figure 7. Impact of NP mAb transfer on influenza infection. Young (2-3 mos.) and aged (19-22 mos.) 
C57BL/6 mice were administered anti-NP mAb or isotype control mAb (350 ug i.p.) on days -1 and day 0. 
On day 0, they were infected intranasally with 400 EID50 of PR8 influenza. A. Weight loss and B. survival 
were monitored following infection. C. On 5 dpi infection, mRNA was prepared from lung tissue from young 
and aged mice to quantitate influenza PA by real-time PCR. D. BAL was also harvested from young and 
aged mice on day 5 and cytokine and chemokine levels were determined by multiplex assay. *p < 0.05 by 
Student’s t-test comparing vaccinated and control groups; **p < 0.05 by Log rank test. Oncotarget33588www.impactjournals.com/oncotarget
Figure 4: Impact of NP mAb transfer on influenza infection. Young (2-3 mos.) and aged (19-22 mos.) C57BL/6 mice were 
administered anti-NP mAb or isotype control mAb (350 ug i.p.) on days -1 and day 0. On day 0, they were infected intranasally with 400 
EID50 of PR8 influenza. A. Weight loss and B. survival were monitored following infection. C. On 5 dpi infection, mRNA was prepared 
from lung tissue from young and aged mice to quantitate influenza PA by real-time PCR. D. BAL was also harvested from young and aged 
mice on day 5 and cytokine and chemokine levels were determined by multiplex assay. *p < 0.05 by Student’s t test comparing vaccinated 
and control groups; **p < 0.05 by Log rank test.
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NP-specific T cells in Vaccinated Mice 
 
Despite aged mice not showing a significant difference in viral clearance or other 
protective flu-related measures following mAb treatment, there could be differences in 
cellular responses to flu in aged mice as a mediator of protection. This, in conjunction 
with data from Figure 2 and Figure 3, the aged environment could have an impact on 
CD4 T cell function, which is important in orchestrating many aspects of flu-mediated 
protection and recovery. As a result, the impact of vaccination of flu NP-specific CD4 T 
cells was examined to see if there was a relationship between age and the number of flu-
specific cells in the lungs and spleens.  
 
As described earlier, CD4 T cells are a large part of the immune response to flu and are 
affected differently depending on the environmental signals they receive. Because there 
is a differential expression of cytokines and chemokines in the young and aged 
environments, it is predicted that there will be altered CD4 T cell responses with age as 
well. CD4 T cells in vaccinated, influenza-infected young and aged groups from Figure 5 
were examined. NP-specific CD4 T cells were enumerated using a MHC class II tetramer 
at 5 dpi. In lungs (Figure 8A) and spleen (Figure 8B), there was a significantly higher 
percentage and number of NP-specific CD4 T cells in the young NP vaccinated groups 
(NP/PR8), compared to the control groups (PBS/PR8). In contrast, NP vaccinated cohorts 
of aged mice did not show any significant enhancement of CD4 T cell numbers in either 
spleen or lungs when compared to controls. Importantly, it is essential for these flu-
specific CD4 T cells to be recruited to the lungs during influenza infection in order to 
quickly and completely clear virus and resolve inflammation (Hufford et al. 2015). The 
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lack of NP-specific T cells in the aged lungs could be a major contributor to slower 
resolution of infection and assessment of later time points after vaccination will be 
explored in Chapter 9. What was most striking about the significant difference between 
flu-specific CD4 T cells in young lungs and spleens was that there were so few T cells in 
the aged tissues. Although no differences were seen between vaccinated and 
unvaccinated aged groups, it is important to take into account the kinetics of CD4 T cell 
responses in aged mice.  
 
Examining the CD4 T Cell Response to Flu Infection in Aged Mice 
 
While the effect of aging on CD8 T cell responses to influenza has been extensively 
studied (Ely et al. 2007; Jiang et al. 2011), the impact on CD4 T cells is less well 
understood. Importantly, TH1 cells are an integral part of the immune response to 
influenza and are crucial to complete resolution of the infection (Altenburg et al. 2015; La 
Gruta et al. 2014). To begin to investigate the impact of aging on CD4 T cells during 
influenza infection, the distribution of T helper subsets in unvaccinated young and aged 
mice was examined at later time points post infection. The NP-specific CD4 T cell 
population was broken down phenotypically into subsets based on PSGL1 (CD162) and 
Ly6C expression to indicate T helper type 1 (TH1, PSGL1hi Ly6Chi), T memory (Tmem, 
PSGL1hi Ly6Clo) and T follicular helper (TFH, PSGL1lo Ly6Clo) precursors (Marshall et 
al. 2011). Representative flow cytometry plots of PSGL1 and Ly6C stained splenic NP-
specific CD4 T cells from young and aged influenza infected mice are shown in (Figure 
9A). The percentage (Figure 8C) and numerical (Figure 9B) distribution of these T helper 
subsets within the spleens of influenza infected mice show that on both 7 and 14 dpi 
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within the total CD4 population and the NP-specific CD4 population, skewing towards TH1 
is more prevalent in the young groups. Furthermore, Figure 8C also demonstrates that 
the percentage of TFH phenotype CD4 T cells in both the total CD4 and NP-specific 
populations was significantly greater in the aged groups. This observation is further 
complemented when we use a more conventional phenotypic analysis of splenic TFH cells.  
CXCR5+PD-1+ TFH percentages and total numbers are higher in aged groups both prior 
to and during influenza infection (Lefebvre and Masters et al. 2016). Thus, with aging 
there is a decrease in TH1 and an increase in TFH differentiation after infection.  
 
Interestingly, the total number of CD4 T cells in the lungs at 7 and 10 dpi is not different 
between young and aged and is only significantly different on 12 dpi (Figure 8D). In the 
lungs during influenza infection we also find a significant skewing of the total CD4 
population towards TH1 in the young and towards TFH in the aged at all time points 
examined. To further assess this subset differentiation, the TH1/TFH ratio of the results 
presented in Figure 8C and 8D was compared. This comparison (Figure 8E) 
demonstrates that during influenza infection in both the lungs and spleen TH1 
differentiation dominates significantly in young groups, while TFH differentiation dominates 
in the aged. This holds true for both the total CD4 population as well as the NP+ tetramer 
population and for all time points examined. Therefore, while the total number of CD4 T 
cells trafficking to the lungs in unvaccinated influenza infected aged mice is not 
significantly different, the T helper subset distribution of these cells is dramatically altered 
and could have an impact on protective immunity.  
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Figure 8. Age-related differences in T cells during influenza infection. Young [Y] (2-3 mos.) and aged 
[A] (19-22 mos.) C57BL/6 mice were vaccinated with NP or PBS on days -31 and -21 and then infected 
with intranasally with 400 EID50 of PR8 influenza on day 0. On 5 dpi lungs and spleens were harvested. 
NP-specific CD4 T cells in the A) lungs and B) spleen were enumerated with an NP311-325/IAb MHC class II 
tetramer. C) On day 0, young and aged unvaccinated mice were infected intranasally with 400 EID50 of PR8 
influenza. On 7 and 14 dpi, the CD4 T cell population was further broken down phenotypically into subsets 
based on PSGL1 (CD162) and Ly6C expression to indicate T helper type 1 (Th1, PSGL1hi Ly6Chi), T 
memory (Tmem, PSGL1hi Ly6Clo) and T follicular helper (Tfh, PSGL1lo Ly6Clo). The percent of each subset 
within the total CD4 and NP-specific CD4 T cell populations is shown. D) On day 0, young and aged 
unvaccinated mice were infected intranasally with 400 EID50 of PR8 influenza. On 7, 10 and 12 dpi, lungs 
were harvested to generate single cell suspensions, which were then stained as in C. Total CD4 numbers 
and percentages within TH1, Tmem and TFH subpopulations are shown. E) Ratio of Th1/Tfh percentages 
from results shown in C. and D. For all, data is representative of 2 independent experiments and each 
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Figure 5: Age-related differences in T cells during influenza infection. Young [Y] (2-3 mos.) and aged [A] (19-22 mos.) 
C57BL/6 mice were vaccinated with NP or PBS on days -31 and -21 and then infected with intranas lly with 400 EID50 of PR8 influenza on 
day 0. On 5 dpi lungs and sp eens were harvested. NP-specific CD4 T cells in the A. lungs and B. spleen were enumerated with a NP311-325/
IAb MHC Class II tetramer. C. On day 0, young and aged unvaccinated mice were infected intranasally with 400 EID50 of PR8 influenza. 
On 7 and 14 dpi, the CD4 T cell population was further broken down phenotypically into subsets based on PSGL1 (CD162) and Ly6C 
expression to indicate T helper type 1 (Th1, PSGL1hi Ly6Chi), T memory (Tmem, PSGL1hi Ly6Clo) and T follicular helper (Tfh, PSGL1lo 
Ly6Clo) according to the scheme developed by Marshall and colleagues [38]. The percent of each subset within the total CD4 and NP-
specific CD4 T cell populations is shown. D. On day 0, young and aged unvaccinated mice were infected intranasally with 400 EID50 of 
PR8 influenza. On 7, 10 and 12 dpi, lungs were harvested to generate single cell suspensions, which were then stained as in C.. Total CD4 
numbers and percentages within Th1, Tmem and Tfh subpopulations are shown. E. Ratio of Th1/Tfh percentages from results shown in C. 
and D.. For all, data is repres ntative of 2 independent experiments and each symbol r pre ents a single a imal; line shows the mean; *p < 
0.05 by 2 way ANOVA with Bonferroni posthoc correction for A, B and D or Student’s t test comparing young vs aged groups for C and E
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symbol represents a single animal; line shows the mean; *p < 0.05 by 2-way ANOVA with Bonferroni 
posthoc correction for A, B and D or Student’s t-test comparing young vs aged groups for C and E.  
 
 
 
Figure 9. CD4 T cell differentiation. A) Representative FACS plot of splenic NP+CD4 T cells on day 14 of 
influenza infection. B) Cell numbers of graphs represented in Figure 8C.  
 
 
Discussion 
  
With age, the immune response to influenza infection diminishes resulting in slower viral 
clearance and increased lung inflammation. In older individuals, the result is exacerbation 
of chronic age-related diseases. This was also observed in this aging mouse model of 
influenza infection. Aged mice were slower to clear virus and exhibited higher levels and 
extended production of inflammatory cytokines and chemokines in BAL fluid when 
compared to young. Furthermore, other cytokines and chemokines important for 
recruitment of an adaptive immune response to influenza infection in the lungs were either 
delayed or produced at significantly lower levels in aged mice. Thus, while inflammation 
is lingering in response to infection, recruitment of virus-specific T cells is delayed due to 
lower levels of lung chemo-attractants. Interestingly, there was not a dramatic difference 
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in either the percentage, number or type of cells in the BAL of aged mice during influenza 
infection. This observation indicates that there may be an increase in the amount of 
cytokine produced per cell in aged lungs, which may be attributed to the higher viral 
burden when compared to young. This could also be an indication that the source of 
inflammation in aged tissues is not simply due to the influx of inflammatory immune cells, 
but of the non-hematopoietic cells within the tissue. Thus, ways to better control viral 
levels, especially in older individuals, are an important clinical goal. One of the easiest 
ways to prevent influenza-related complications is by vaccination and previous work has 
shown that vaccination can prevent lung inflammation following influenza infection in 
young mice (Haynes et al. 2012). In this study we have gone on to examine the overall 
protection induced by NP vaccination in aged mice.  
 
It is well documented that the efficacy of influenza vaccination declines with aging (Beyer 
et al. 2013; Lamere et al. 2011a), but the exact mechanisms responsible for this remain 
elusive. Here, the efficacy of an influenza vaccine consisting of the highly conserved 
influenza NP protein has been examined. This vaccine was chosen because it has been 
shown to induce a protective heterosubtypic antibody response in young mice (Lamere 
et al. 2011a; Lamere et al. 2011b). It is shown here that NP vaccination of aged mice did 
protect from death following influenza infection but did not protect from influenza-induced 
weight loss and did not reduce inflammation, albumin levels, or viral quantities in the lungs 
after subsequent infection. In contrast, NP vaccination did induce a significant amount of 
NP-specific IgG in aged mice compared to unvaccinated aged, although this amount was 
less than what was generated in young mice. Adoptive transfer of a NP-specific 
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monoclonal antibody to aged influenza-infected mice had protective capacity similar to 
NP vaccination, indicating that some of the protective capacity of the vaccination may be 
working via an antibody-dependent mechanism.  
 
In addition to production of NP-specific antibodies, young, but not aged, NP vaccinated 
mice given a subsequent influenza infection also develop NP-specific CD4 T cells in the 
lungs and spleen very early (day 5) during infection. CD4 T cell effectors in the lungs have 
been shown to be extremely important in viral clearance and can be cytotoxic toward 
virally infected cells (Brown et al. 2006; Sun et al. 2011). Thus, it is likely that the presence 
of these CD4 T cells is helping to dampen inflammatory mediators in the young lungs 
during infection, especially since these mice have very low levels of albumin in their lungs 
indicating minimal lung damage. These results are very interesting since a study from the 
Blackman laboratory demonstrated that there is a significant delay in influenza-specific 
Th1 effector CD4 T cell appearance in the lungs during infection (Lanzer et al. 2014). So, 
it seems that while the CD4 T cell response needed to generate an antibody response in 
our aging model is adequate, the ability to generate lung-homing Th1 effectors during 
influenza infection is less preserved with aging. This could account for the reduced ability 
to control lung inflammatory mediators that we observed. 
 
Importantly, these results point to a novel finding that the two mechanisms of vaccine-
mediated protection, antibody and lung-homing T cell effector generation, seem to be 
differentially affected by aging. In order to understand what is happening in this aging 
model, CD4 T cells of influenza-infected mice were briefly examined to determine if there 
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was any impact of age on Th subset differentiation. Interestingly, it was found that in both 
the total CD4 T cell population and the influenza NP-specific CD4 T cell population there 
was a significant skewing towards a TFH phenotype in aged groups. In contrast, young 
CD4 T cells exhibited a skewing towards a TH1 phenotype, which is important for control 
of virus and inflammation in the lungs. This is seen most clearly when we compare the 
TH1 to TFH ratios, where most of the ratios from aged cohorts are less than 2 and those 
from young cohorts range to over 50. These results confirm those of Sage and colleagues 
(Sage et al. 2015) who also reported similar enhancement of the TFH population in aged 
mice. This difference in T helper subset distribution between young and aged groups 
could account for the fact that aging has a greater impact on the generation of lung-
homing TH1 effectors rather than on TFH cells and antibody production. Whether this 
apparent preference for TFH differentiation is intrinsic to aged CD4 T cells or is induced 
by the aged microenvironment is to be determined later in this thesis.  
 
Nonetheless, this knowledge of differences in T helper subset distribution with aging could 
help further our understanding of how aging impacts immunity to both infections and 
vaccinations. It could be important to develop a vaccine that is tailored to enhancing 
specific CD4 T cell subsets with age to generate robust protective immunity. Finally, these 
results also stress why it is important to examine multiple parameters, such as both 
humoral and cellular aspects of immunity, when testing preventative or therapeutic drugs 
in the aging population. Because these results have demonstrated a clear difference in 
the kinetics and magnitude of responses to flu between young and aged mice, the 
remainder of this thesis work will focus heavily on aged mice. While comparing the impact 
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certain interventions have on the CD4 T cells in young and aged groups is important, the 
remainder of this work will focus on the effects of altering the CD4 T cell responses in 
aged mice in comparison to unvaccinated or untreated age-matched counterparts 
separately from young.  
 
The next set of studies addressed the ability of vaccination to alter the CD4 T cell subsets 
in aged mice over the course of flu infection. It was hypothesized that vaccination with an 
adjuvant polarizing CD4 T cells to differentiate to a TH1 phenotype would enhance the 
response seen in aged mice, shifting it from a more TFH response, critical to enhancing 
humoral responses, to a TH1 response, critical for enhancing cellular mediated responses 
to flu in the lung. There are a variety of ways to alter the immune response and several 
are discussed here (Figure 10).  
 
Figure 10. Potential strategies to alter the aged environment and shift CD4 T cell subsets. There are 
many potential strategies that can enhance flu immunity and CD4 T cell subset differentiation. Discussed 
in this thesis are three strategies: I) priming of CD4 T cells using vaccination by combining flu NP peptide 
and adjuvant, II) using TGF-β neutralizing antibody to prevent senescence and preferential differentiation 
of CD4 T cells to a Treg phenotype early on in the flu response, and III) using senolytic drugs to eliminate 
senescent cells that alter the aged tissue environment, potentially by secretion of TGF-β. By manipulating 
the aged environment, we examined if any of these strategies can have an impact on flu responses and/or 
CD4 T cell subset distribution within affected tissues. This figure was created with BioRender.com. 
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CHAPTER NINE 
 
 
Examining the Effects of Vaccination on Aged CD4 T Cell 
 
Vaccination can protect aged mice from flu  
 
Aging has a profound impact on many flu-related responses. We hypothesized, based on 
the data above, that dysregulated responses in the aged environment could be driving 
CD4 T cells to have altered differentiation in the mediastinal lymph nodes and expansion 
in the lungs, preferential to a TFH or Treg phenotype. To assess the kinetic effects of 
vaccination on the overall flu response, mice were vaccinated and intranasally infected 
as described (Figure 11A). In addition, to using recombinant NP protein as the antigen 
stimulation in this vaccine construct, AddaVax, an MF59-like adjuvant (described in the 
introduction) is used in order to drive the immune response to be more robust.  
 
To determine the effect of vaccination on flu viral clearance, viral copy number was 
quantified (Figure 11B). By 9 dpi, there was a significant, reduction in viral quantity in the 
lungs of aged mice, indicating that viral clearance does occur at later time points in aged 
lungs. There was also a significant increase in anti-NP IgG antibodies in the BAL of young 
and aged lungs over time (Figure 11C). As expected, vaccination in young mice 
enhanced NP-specific antibody production faster and it remained elevated over the 
course of 9 dpi. The aged vaccinated mice also showed increased antibody production 
compared to the unvaccinated group which also significantly increased over time. This 
was surprising given that reports using aged mouse models indicate that, with age, 
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antibody production decreases (Lefebvre and Masters et al. 2016), yet could be rescued 
almost entirely by prior vaccination. Aged vaccinated mice also regained weight 
significantly faster at 8 and 9 dpi compared to unvaccinated groups (Figure 11D), 
indicating that NP/AddaVax vaccination is playing a positive role in flu responses in aged 
mice. The next set of experiments address the impact of vaccination on inflammatory 
mediators at later time points in aged mice.  
 
FIGURE 11. Priming the immune system using NP-flu vaccination protects young and aged mice 
from hallmarks of influenza-induced complications. A) Young (2-3 months) and aged (18-20 months) 
C57BL/6 mice were vaccinated and subsequently infected for analysis performed. Figure was created with 
BioRender.com B) On 9 dpi, lungs were harvested at peak infection and mRNA was isolated to quantitate 
influenza PA copy number by real-time PCR. C) Anti-NP IgG titers in the serum were determined by ELISA 
at 5, 7, and 9 dpi. D) Weight loss over the course of infection was measured and normalized to starting 
weight. Data shown is combined from at least four independent experiments with a total of 5-15 mice per 
group. Statistical significance was calculated by Student’s t-test comparing unvaccinated and vaccinated 
groups (b) and 2-way ANOVA with Bonferroni correction (c and d). The data is presented as 
means ± standard error of the mean (SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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Assessing Inflammatory Mediators in Aged BAL 
 
 
When considering the contribution of the aged environment and inflammation, many 
inflammatory mediators were examined to determine if vaccination of aged mice could 
regulate inflammation over the course of flu infection. In Figure 12A, inflammatory 
cytokine production was seen to be significantly dampened at 9 dpi in the BAL of aged 
mice when the immune system was primed by NP vaccination. The reduction in all of 
these inflammatory mediators, could be very important in regulating inflammatory cell 
recruitment and CD4 T cell responses in the lung and will be addressed separately. In the 
unvaccinated groups, the chemokines and cytokines examined here show a delay in 
control during the response, which could be responsible for lung damage seen and higher 
albumin levels seen in unvaccinated, flu infected mice (Figure 2B). As shown in Figure 
2A, influenza virus is beginning to be cleared at about 9 dpi. Having significantly higher 
inflammatory mediators at this time point in unvaccinated mice is an indication that 
resolution is delayed and vaccination may help counter these effects. One indication of 
flu viral clearance is the resolution of type-I interferons (IFN) like IFN-α and IFN-β, which 
has been extensively studied in the context of viral immunity (Killip et al. 2015). Here, it 
is interesting to see that both IFN-α and IFN-β are significantly reduced in the BAL of 
vaccinated aged mice. While IFN-α and IFN-β are meant to resolve during the early 
stages of the flu response, as seen in the vaccinated groups, the unvaccinated groups 
maintain higher levels at five dpi (Figure 12B). This coincides with significantly lower viral 
titers seen in Figure 11B.  
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FIGURE 12. NP-flu vaccination significantly reduces lung inflammation associated with leukocyte 
recruitment and anti-viral responses. Aged C57BL/6 mice (18-20 months) were vaccinated and 
subsequently infected for analysis performed as described in Figure 10. A) On 5, 7, and 9 dpi, 
bronchialveolar lavage (BAL) was isolated prior to removal of lung tissue. Inflammatory factors in the BAL 
were assessed using multiplex analysis. B) At 5 dpi, type I interferons α and β (IFN-α and IFN-β, 
respectively) in the BAL of aged mice was determined by ELISA. Data shown is combined from at least 
four independent experiments with a total of 5-15 mice per group. Statistical significance was calculated by 
2-way ANOVA with Bonferroni correction (a) and Student’s t-test comparing unvaccinated and vaccinated 
groups at each respective dpi (b). The data is presented as means ± standard error of the mean (SEM). 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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IFN-γ peaked at 5 dpi in the vaccinated aged mice, which could suggest that there are 
fewer TH1 CD4 T cells in the lung (Figure 13A). Interestingly, whereas in the 
unvaccinated aged groups there was significantly less type II cytokines, such as IL-4 and 
IL-5, these cytokines were higher at 9 dpi in the vaccinated mice. This could suggest that 
not only does vaccination aid in the control of inflammation and production of type I 
interferons, it could enhance a recovery, type II CD4 T cell response at later time points. 
This leaves open avenues to study type II responses to flu infection in primed aged mice 
in the future. Additionally, as IFN-γ peaked at 5 dpi, IL-10 levels began to rise with a 
significantly higher level compared to unvaccinated mice by 9 dpi (Figure 13B). This is 
yet another indication that priming the immune system with flu vaccination regulates 
inflammation and may provide some control in regulating inflammatory: anti-inflammatory 
and regulatory CD4 T cell responses as described earlier in the introduction.  
 
Further examination of chemokines necessary for immune cell recruitment also seems to 
be regulated in vaccinated mice (Figure 14). With the dampening of inflammatory cell 
recruitment into the tissues, there could be protection of the lung tissue, as opposed to 
having aberrant inflammation. It is also clear that while inflammation is resolving in the 
vaccinated aged groups, the unvaccinated mice have a higher level of and delay in 
inflammatory secretion. This is additional evidence that not only does vaccination protect 
aged mice from enhanced inflammation, it also regulates it so there is a necessary 
inflammatory phase and a resolution phase. Taken altogether, the importance of having 
a balance in inflammation is critical to mounting effective flu responses. As discussed 
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earlier, however, one of the key factors in determining an effective immune response to 
vaccination and flu infection is the effect on CD4 T cells.   
 
FIGURE 13. NP-flu vaccination regulates type I inflammatory mediators and induces stronger type 
II inflammation associated with CD4 T cells in aged mice. Aged C57BL/6 mice (18-20 months) were 
vaccinated and subsequently infected for analysis performed as described in Figure 10. On 5, 7, and 9 dpi, 
A) pro- and B) anti-inflammatory factors in the BAL (IFN-ɣ, IL-17, and IL-13) and serum (IL-4, IL-5, and IL-
10) were assessed using multiplex analysis. Data shown is combined from at least four independent 
experiments with a total of 5-15 mice per group. Statistical significance was calculated by 2-way ANOVA 
with Bonferroni correction comparing unvaccinated and vaccinated groups at each respective dpi. The data 
is presented as means ± standard error of the mean (SEM). *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001. 
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FIGURE 14. NP-flu vaccination controls chemo-attractant secretion in BAL of infected aged mice. 
Aged C57BL/6 mice (18-20 months) were vaccinated and subsequently infected for analysis performed as 
described in Figure 10. On 5, 7, and 9 dpi, chemo-attractant proteins in the BAL and serum were determined 
by multiplex analysis. Data shown is combined from at least four independent experiments with a total of 
5-15 mice per group. Statistical significance was calculated by 2-way ANOVA with Bonferroni correction 
comparing unvaccinated and vaccinated groups at each respective dpi. The data is presented as 
means ± standard error of the mean (SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.  
 
 
Determining the Effect of Vaccination on CD4 T Cell Subsets 
 
 
After determining that the aged lung environments in vaccinated and unvaccinated mice 
have strikingly different inflammatory profiles, dependent on priming of the immune 
system, it is hypothesized that this could have an effect on the regulation of CD4 T cell 
differentiation and subsets in flu response-associated tissues. There are three important 
sites where CD4 T cells can be assessed, the mediastinal lymph node, the lungs and the 
spleen. The mediastinal lymph node (MLN) is the draining lymph node of the lung, making 
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this one of the first sites where flu responses outside of the lung will occur. It is also critical 
to examine the CD4 T cell response in the lung, being the site of flu infection and viral 
replication. The spleen also plays a role in flu immunity and has been shown to provide a 
large pool of TFH cells to respond to infection and boost germinal center reactions (Boyden 
et al. 2012). Therefore, CD4 T cells within these tissues important in the response to flu 
infection are examined. In young mice, it is was expected that a balance of CD4 T cells 
would be seen, with a higher percentage of flu specific cells in the MLN at all time points 
post infection, before migration to the lung, which would explain the higher numbers of 
CD4 T cells in the lung by 9 dpi (Figure 15A).  
  
Surprisingly, however, there was not a significantly higher percentage of flu specific CD4 
T cells in the aged lungs in the vaccinated group (Figure 15B). In contrast, the MLN and 
spleen did show significant differences compared to unvaccinated mice. The primed CD4 
T cells in the MLN showed higher percentages at 5 and 7 dpi, whereas unprimed CD4 T 
cells did not increase until much later at 9 dpi. This could be indicative of environmental 
decrements that vaccination may help ameliorate to provide an environment that 
promotes controlled levels of CD4 T cells and potentially efficient migration. In the aged 
spleens (Figure 15B), there are significantly more flu specific CD4 T cells at 7 and 9 dpi 
as compared to unvaccinated mice.  
 
This leads to the question of how these flu specific CD4 T cells are differentiating and 
which subsets are predominant in different tissues. As a result, transcription factors were 
used to identify TH1, TFH, and Treg CD4 T cells. As described earlier, Tbet is the 
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transcription factor used to identify TH1, Bcl6 to identify TFH cells, and FoxP3 to identify 
Treg CD4 T cells.  
   
 
 
Examining the subset differentiation in CD4 T cells is important since they have specific 
functions that are essential to orchestrating different aspects of the flu response. 
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FIGURE 15. NP-flu vaccination alters flu NP-specific CD4 T cell subsets in aged tissues 
following flu infection. Young (6-8 weeks old) and aged (18-20 months) C57BL/6 mice were 
vaccinated and subsequently infected as described in Figure 10. On 5, 7, and 9 dpi, lung, MLN, and 
spleen tissues were harvested. NP-specific CD4 T cells were then enumerated out of the total CD4 T 
cell population with an NP
311-325
/IA
b
 MHC class II tetramer. A) Shows the percentage of NP+ cells 
within the total CD4 T cell compartment in the lung, MLN, and spleens of young mice at each dpi, 
while B) shows the same comparisons, but in aged mice. This data was determined by flow cytometry. 
Data shown is combined from at least four independent experiments with a total of 5-15 mice per 
group. Statistical significance was calculated by 2-way ANOVA with Bonferroni correction comparing 
unvaccinated and vaccinated groups at each respective dpi. The data is presented as 
means ± standard error of the mean (SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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Alterations in CD4 T cell subsets that can further hinder the flu response can be 
detrimental to the vulnerable aging population. In the lungs (Figure 16), it is very 
interesting that vaccination seems to dampen the TH1 and Treg percentages within the 
flu-specific CD4 T cell populations of aged lungs. The unvaccinated groups have 
significantly higher percentage of both of these subtypes by 7 dpi. This was contrary to 
the hypothesis that vaccination would boost TH1 responses, as discussed in the 
introduction. Moreover, an observation can be made that the percentages in the FoxP3 
subsets in the aged mice seen over time are comparable to the unvaccinated young. It is 
a possibility that instead of ramping up the immune response in aged mice by promoting 
more TH1 cells to balance Treg subsets, that a regulated and lower amount of both 
subsets is required. This result slightly changes the perspective of aging research, where 
more is considered better.  
 
 
While there was no significant difference in the percentages of TFH cells in the MLN, there 
was a significant reduction in the percentage of the TH1 cells at 5 and 9 dpi and the Treg 
cells at all time points in the vaccinated group (Figure 17). This coincides with the 
previous thought that perhaps a balance of inflammatory and regulatory CD4 T cells must 
be achieved to have effective CD4 T cell responses in flu infection and that vaccination 
may be a way to achieve this. The observation that percentages of CD4 T cells in the 
aged MLNs are similar to the young unvaccinated groups also hold true for the TH1 and 
Treg subsets. It is clear, however that CD4 T cell subsets are altered with age but can be 
regulated using vaccination.  
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FIGURE 16. NP-flu vaccination alters CD4 T cell subsets in aged lung following flu infection. 
Young (6-8 weeks old) and aged (18-20 months) C57BL/6 mice were vaccinated and subsequently 
infected as described in Figure 10. On 5, 7, and 9 dpi, lung tissues were harvested. NP-specific CD4 
T cells were then enumerated out of the total CD4 T cell population with an NP
311-325
/IA
b
 MHC class II 
tetramer at each dpi. The percentage of NP+ cells within the total CD4 T cell compartment were then 
assessed for expression of subset-specific transcription factors. Tbet is expressed in T
H
1 cells, Bcl6 
is expressed in T
FH
, and FoxP3 is expressed in Treg cells. The top row of this figure shows the 
percentage of these subsets in vaccinated and unvaccinated young mice, while the bottom row shows 
the same comparisons, but in aged mice. This data was determined by flow cytometry. Data shown is 
combined from at least four independent experiments with a total of 5-15 mice per group. Statistical 
significance was calculated by 2-way ANOVA with Bonferroni correction comparing unvaccinated and 
vaccinated groups at each respective dpi. The data is presented as means ± standard error of the 
mean (SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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Changes in the spleen of aged mice were only observed in the FoxP3 subset of CD4 T 
cells at 5 and 7 dpi (Figure 18). In the young mice, however, a significant percentage of 
cells in the spleen are TFH at 7 dpi. This coincides with research showing that the spleen 
has a significant impact on TFH subset differentiation after flu infection (Boyden et al. 2012; 
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FIGURE 17. NP-flu vaccination alters CD4 T cell subsets in aged MLN following flu infection. 
Young (6-8 weeks old) and aged (18-20 months) C57BL/6 mice were vaccinated and subsequently 
infected as described in Figure 10. On 5, 7, and 9 dpi, MLN tissues were harvested. NP-specific CD4 
T cells were then enumerated out of the total CD4 T cell population with an NP
311-325
/IA
b
 MHC class II 
tetramer at each dpi. The percentage of NP+ cells within the total CD4 T cell compartment were then 
assessed for expression of subset-specific transcription factors. Tbet is expressed in T
H
1 cells, Bcl6 
is expressed in T
FH
 and FoxP3 is expressed in Treg cells. The top row of this figure shows the 
percentage of these subsets in vaccinated and unvaccinated young mice, while the bottom row shows 
the same comparisons, but in aged mice. This data was determined by flow cytometry. Data shown is 
combined from at least four independent experiments with a total of 5-15 mice per group. Statistical 
significance was calculated by 2-way ANOVA with Bonferroni correction comparing unvaccinated and 
vaccinated groups at each respective dpi. The data is presented as means ± standard error of the 
mean (SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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Lefebvre and Masters et al. 2016). This significant increase was not, however, seen in 
the aged mice and could indicate that either the spleen does not support the TFH 
population as well as in the young mice or that other environmental decrements in the 
spleen cannot be rescued with vaccination to promote a more robust TFH response. These 
data from Figures 16, 17, and 18 can be taken together to conclude that although there 
are very significant differences in the subset distribution of unvaccinated aged CD4 T cells 
that could support and also be a result of skewed environmental cues in aged tissues, 
that balance between the subsets can be reached with vaccination. While the functional 
outcomes of these subset changes remain to be determined and will be examined in 
future studies in the laboratory, these are the first studies to examine the effects of the 
aging in the context of NP vaccination with an adjuvant as methods to alter the CD4 T 
cell responses. This reinforces the fact that although aged CD4 T cells have cell intrinsic 
decrements, discussed earlier, changes in the aged environment may rescue the CD4 T 
cell imbalance that occurs with flu and age.  
 
One of the most apparent changes with age was within the FoxP3+ compartment of CD4 
T cells. When examining vaccinated aged mice, FoxP3 expressing flu-specific CD4 T 
cells are significantly reduced in all three tissues. As discussed before in the introduction, 
Treg cells have immunosuppressive power that can dampen inflammatory responses, 
promoting stronger regulatory and type II responses and impair the inflammatory immune 
response to flu.  
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Preliminary Examination of TGF-β in Aged Vaccinated Mice 
 
In determining the source of environmental changes in the aged environment that could 
impact CD4 T cell differentiation, one factor that leads to and reinforces senescence was 
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FIGURE 18. NP-flu vaccination alters CD4 T cell subsets in aged spleen following flu infection. 
Young (6-8 weeks old) and aged (18-20 months) C57BL/6 mice were vaccinated and subsequently 
infected as described in Figure 10. On 5, 7, and 9 dpi, spleen tissues were harvested. NP-specific 
CD4 T cells were then enumerated out of the total CD4 T cell population with an NP
311-325
/IA
b
 MHC 
class II tetramer at each dpi. The percentage of NP+ cells within the total CD4 T cell compartment 
were then assessed for expression of subset-specific transcription factors. Tbet is expressed in T
H
1 
cells, Bcl6 is expressed in T
FH
 and FoxP3 is expressed in Treg cells. The top row of this figure shows 
the percentage of these subsets in vaccinated and unvaccinated young mice, while the bottom row 
shows the same comparisons, but in aged mice. This data was determined by flow cytometry. Data 
shown is combined from at least four independent experiments with a total of 5-15 mice per group. 
Statistical significance was calculated by 2-way ANOVA with Bonferroni correction comparing 
unvaccinated and vaccinated groups at each respective dpi. The data is presented as 
means ± standard error of the mean (SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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examined. TGF-β, as described earlier is a pleotropic cytokine secreted by many cell 
types, especially in the context of flu infection, that impacts surrounding cells and has a 
significant impact on Treg cells. In addition, it was shown in Figure 12B that IFN-α and 
IFN-β was significantly reduced in vaccinated aged mice, correlating with significantly 
reduced viral clearance. We hypothesized that TGF-β production would be reduced  in 
vaccinated aged mice, which could play a large role in the regulation of CD4 T cell and 
overall flu responses. It has been shown that TGF-β derived from lung epithelial cells acts 
as a pro-viral factor in mice infected with flu, by suppressing IFN-β responses (Denney et 
al. 2018). In fact, knocking out TGF-β in epithelial cells resulted in a significant increase 
in IFN-β and significantly increased viral clearance (Denney et al. 2018).  
 
In relation to these studies, it is possible that reduced TGF-β secretion in the lungs of 
vaccinated aged mice during infection, could be the reason for reduced levels of Treg 
cells and increased viral clearance seen in aged lungs. To examine this question, of 
whether vaccination reduced TGF-β in aged mice, TGF-β ELISA was performed to 
quantify the presence of active TGF-β in vaccinated and unvaccinated BAL fluid (Figure 
19). In young vaccinated mice, TGF-β was actually significantly increased when 
compared to unvaccinated controls. This could coincide with the fact that viral clearance 
occurs much faster in young mice than aged, therefore TGF-β, may not be inhibiting viral 
clearance in a young environment. In contrast, vaccinated aged mice have significantly 
lower levels of TGF-β in the BAL when compared to the unvaccinated group. This was 
interesting to see and consider as a potential mechanism of vaccination regulating the 
immune response to flu. While these are preliminary studies, much more work needs to 
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be done to fully examine the role of TGF-β in vaccination. It would be very interesting to 
use a lung epithelial-specific TGF-β knockout mouse to examine the contribution of 
epithelial cell-derived TGF-β in the aged microenvironment on CD4 T cell subset changes 
with vaccination and flu infection. It is also, on the other hand, unclear as to the major 
source of TGF-β within aged lungs that drives pathology.  
 
 
 
 
 
To begin to answer the question of whether or not TGF-β is a potential driver of CD4 T 
cell subtype alterations following flu infection, aged mice were infected with PR8 flu and 
given a TGF-β neutralizing antibody via i.p. injection as illustrated in Figure 20A. 
Significant changes were observed in the FoxP3+ population Figure 20B and C. Within 
the total CD4 T cell population (Figure 20A) as well as the NP-specific CD4 T cell 
population (Figure 20B), the FoxP3+ populations are significantly reduced in the TGF-β 
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FIGURE 19. TGF-β production is reduced in vaccinated aged mice, indicative of controlled 
inflammation, CD4 T cell responses, and viral clearance. Aged C57BL/6 mice (18-20 months) and young 
mice (6-8 weeks) were vaccinated and subsequently infected for analysis performed as described in Figure 
1. On 5, 7, and 9 dpi, TGF-β in the BAL was determined by ELISA. The dotted line represents the average 
level of TGF- β measured on 0 dpi. Data shown is combined from at least four independent experiments 
with a total of 5-15 mice per group. The dotted line represents the levels of TGF-β seen in the naive groups 
and serves as a reference for a baseline reading. Statistical significance was calculated by 2-way ANOVA 
with Bonferroni correction comparing unvaccinated and vaccinated groups at each respective dpi (naïve 
group was not taken into account statistically). The data is presented as means ± standard error of the mean 
(SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
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neutralizing antibody groups. This suggests that exogenous TGF-β secreted during flu 
infection could be one of the reasons for flu-induced enhancement of Treg populations in 
aged mice. There were no differences observed in TH1 or TFH populations (data not 
shown). In addition to CD4 T cell studies, NP-specific IgG as well as total flu antibodies 
and viral quantity were measured, however, showed no difference between treated and 
untreated groups (data not shown). Although no changes were observed in these 
measures, it is very interesting that the FoxP3+ CD4 T cell and flu-specific subsets can be 
altered in aged lungs.  
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FIGURE 20. Neutralization of TGF-β in aged mice reduced the percentage of FoxP3+ cells in the 
lungs. A) Aged C57BL/6 mice (18-20 months) were treated with anti-TGF-β neutralizing monoclonal 
antibody (TGF-B mAb) (BioXcell, clone: 1D11.16.8) or IgG isotype control (IgG Ctrl) on 2, 4, 6, 8, and 10 
dpi of flu infection. Mice were sacrificed on 12 dpi and the lungs were harvested for flow cytometry to 
determine the effect of TGF-β neutralization on CD4+ Treg subsets in B) the total CD4 T cell compartment 
and C) the NP-specific CD4 T cell compartment using an NP
311-325
/IA
b
 MHC class II tetramer. Data shown 
is from one experiment with a total of 5 mice per group. Statistical significance was calculated by Student’s 
t-test comparing TGF-β mAb treated and IgG isotype control groups. The data is presented as 
means ± standard error of the mean (SEM). *p < 0.05.  
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In addition to FoxP3+ CD4 T cell subset reduction in TGF-β neutralizing mAb treated 
aged mice, cytokine and chemokine expression was also altered. Most notable, was 
that inflammatory CD4 T cell-associated factor IFN-γ is significantly reduced by 9 dpi 
indicative of viral clearance and reduced inflammation in the lungs (Figure 21A). IL-2 is 
significantly increased at 9 dpi, which could suggest that the reduction of Treg cells 
increases the bioavailability of IL-2 in the lungs (Figure 21A). It would be interesting to 
determine if TH2 CD4 T cells, important during the resolution phase of the flu response, 
is increased by days 12 and 14. Finally, macrophage-associated inflammatory factors 
CCL4 and CXCL2 are significantly upregulated on 9 dpi, which suggests a more robust 
macrophage response is induced when TGF-β is reduced in the lungs (Figure 21B). 
Leukemia inhibitory factor (LIF) was also reduced at 12 dpi, indicating a reduction in 
prolonged inflammation and could be indicative of flu resolution (Figure 21B). 
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FIGURE 21. Neutralization of TGF-β in aged mice alters cytokines and chemokines in the lungs.  
Aged C57BL/6 mice (18-20 months) were treated with anti-TGF-β neutralizing monoclonal antibody (TGF- 
β mAb) (BioXcell, clone: 1D11.16.8) or IgG isotype control (IgG Ctrl) on 2, 4, 6, 8, and 10 dpi of flu infection. 
On 9, 12, and 14 dpi, mice were sacrificed and chemo-attractant proteins that are A) involved in leukocyte 
recruitment, B) associated with CD4 T cell inflammatory subsets and expansion, and C) secreted by 
inflammatory macrophages in the BAL were determined by multiplex analysis. Data shown is from one 
experiment with a total of 5 mice per group. Statistical significance was calculated by Student’s t-test 
comparing TGF-β mAb treated and IgG isotype control groups. The data is presented as means ± standard 
error of the mean (SEM). *p < 0.05, **p < .01.  
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CHAPTER TEN 
 
 
Examination of Senescence in Aged Mice 
 
 
It has been shown that TGF-β plays a large role in senescence, as discussed in the 
introduction, which in turn, is hypothesized to drive the aged-related decrements of the 
tissue environment. Even further, this is hypothesized to influence CD4 T cell 
differentiation. To examine the role of senescence in the aged environment, D+Q, as 
described earlier, was used to eliminate senescent cells in wild-type aged mice prior to 
flu infection (Figure 22A). At 12 dpi, mice were examined for their CD4 T cell subset 
distribution within the lungs. There were no differences between subsets observed in the 
MLNs or spleens at this time point (data not shown). Here, however, lungs of aged mice 
that have been treated with D+Q show a significant reduction in the number and 
percentage of total CD4 T cells in the lungs expressing FoxP3 (Figure 22B). This 
indicates that D+Q can, in fact, control the Treg responses in aged mice, which is 
important in enhancing the response to flu.  
 
Experiments using this cohort were also performed to assess flu-specific IgG antibody 
generation, TGF-β secretion in the BAL, as well as viral clearance, however, none of 
these parameters were significant at this 14 dpi time point. Interestingly, TGF-β was 
significantly down-regulated at 7 dpi (Figure 22C). This indicates that senescent cells 
may be major producers of TGF-β in the aged lung. When selectively eliminated using 
D+Q, this reduction in TGF-β coincides with the reduced FoxP3+ CD4 T cell and FoxP3+ 
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NP-specific CD4 T cells in the lungs at 12 dpi (Figure 22B). It also shows that TGF-β may 
be secreted at earlier time points by senescent cells in the lung after flu infection.  
 
Analysis of kinetics of this response are essential, to accurately determine the effects of 
D+Q on the aged environment and response to flu. The lack of other positive results could 
be attributed to the fact that earlier time points are necessary to establish a full picture of 
the effect senolytic drugs have on aged mice and flu infection. Nonetheless, this is the 
first attempt to examine the effect of D+Q in an aging mouse model of flu infection. With 
additional studies underway, it is possible that other senolytic drugs could be used to 
determine a mechanism for senescence induced changes in the response to flu infection 
and altered CD4 T cell responses with age.  
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Using another model to examine the contribution of senescence in the lung, middle-aged 
12 month old p16-3MR mice were infected with flu and assessed for RFP expression, 
indicative of p16 upregulation and cellular senescence. Interestingly, flu transiently 
induces senescence in middle-aged mice following flu infection (Figure 23A). This was 
seen at two weeks post-infection and was diminished by four weeks in the lung. This is 
of particular interest, especially because of the role senescent cells play in wound healing 
(Demaria et al. 2014). What is not known is if senescent cells induced from flu infection 
have long lasting effects on the function and integrity of lung tissue with age.  
 
To get a glimpse of what occurs within the lung following infection, endothelial cells 
(CD45-CD31+) were examined for their expression of RFP (indicative of p16 expression) 
by flow cytometry. In addition to quantification of RFP expression, the amount of latent 
TGF-β on the surface of the endothelial cells was quantified because endothelial cells are 
one of the main drivers of pathology in aged lungs after flu infection (Teijaro et al. 2011). 
TGF-β is secreted as part of a latent associated protein (LAP) complex that is anchored 
to the extracellular matrix (Saharinen et al. 1996). When TGF-β is released, via proteolytic 
activators, it is cleaved from the LAP complex and can act on surrounding receptors and 
tissues (Annes et al. 2003). LAP complexes, however, degrade following TGF-β release 
FIGURE 22. Senolytic drug combination D+Q induces changes in FoxP3+ CD4 T cell subsets in the 
lung at 12 dpi and TGF-β in the BAL at 7dpi. A) Aged C57BL/6 mice (18-20 months) were treated with 
D+Q before flu infection. B) Mice were sacrificed on 12 dpi and the lungs were harvested for flow cytometry 
to determine the effect of D+Q treatment on CD4+ Treg subsets. C) Free-active TGF-β was measured in 
the BAL and analyzed by ELISA on 7dpi. Data shown is from one experiment with a total of 5 mice per 
D+Q treated group and 6 mice per vehicle treated group. Statistical significance was calculated by 
Student’s t-test comparing D+Q and Veh treated groups. The data is presented as means ± standard error 
of the mean (SEM). *p < 0.05. **p < 0.01.  
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(Hara et al. 2015). As a result, the measure of LAP on endothelial cells can provide 
evidence for TGF-β activation in the lung. Out of the total cells in the lung, the percentage 
of total endothelial cells is significantly reduced in influenza infected mice when compared 
to uninfected controls (Figure 23B). Importantly, the percentage of endothelial cells that 
express LAP is significantly reduced in both infection doses when compared to naïve 
controls, suggesting that less LAP would mean more TGF-β release. To test this further 
however, supernatants from isolated and cultured endothelial cells would have to be 
collected and confirmation by ELISA to measure the actual release of active TGF-β. In 
addition, endothelial cells show a strikingly significant increase in RFP expression by flow 
cytometry following infection. This clear induction of RFP is very interesting because it is 
indicative of p16 upregulation, which may indicate endothelial cell senescence. Moreover, 
quantification of endothelial cells, LAP expression, and RFP expression are not 
significantly affected by the dose of flu when comparing 500EID50 PR8 dose to 700EID50 
PR8 (Figure 23B, C, and D).  
 
	 98	
 
 
 
 
  
Naive 500 700
70
75
80
85
90
95
100
Endothelial Cells
%
 T
ot
al
 E
nd
ot
he
lia
l C
el
ls ****
***
Naive 500 700
95
96
97
98
99
100
%
 L
A
P+
 E
nd
ot
he
lia
l C
el
ls
Endothelial LAP
***
***
Naive 500 700
0
10
20
30
%
 R
FP
+ 
En
do
th
el
ia
l C
el
ls
Endothelial RFP
****
****
B. C. D. 
Naive 2 4 6
0
1
2
3
4
5
Weeks Post Infection
%
 T
ot
al
 R
FP
 in
 L
un
g
Lung Tissue
****
****
****
A.  
FIGURE 23. p16 and latent TGF-β expression are differentially expressed on endothelial cells 
following flu infection. A) Middle aged p16-3MR mice (12-14 months) were given either 500 or 700 EID
50
 
PR8 intranasally in PBS either, 50uL or 70uL, respectively (as indicated). RFP expression, driven by the 
p16 promoter in the p16-3MR construct, in lung cells was quantified at 0, 2, 4, or 6 weeks post infection by 
flow cytometry. B) p16-3MR mice were also used to quantify total % of endothelial cells in the lung after 14 
dpi flu infection, as described in A. They were also used to quantify endothelial cells expressing C) TGF-β 
latency associated protein (LAP) and D) p16 associated RFP expression using flow cytometry. Endothelial 
cells were CD45-CD31+. Data shown is from two independent experiments with a total of 5-10 mice per 
group. Statistical significance was calculated by 2-way ANOVA with Bonferroni correction comparing naïve 
and flu infected groups at each respective dpi. The data is presented as means ± standard error of the 
mean (SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
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CHAPTER ELEVEN 
DISCUSSION 
In Summary  
 
 
Figure 24. Graphical Summary. It is proposed in this thesis that TGF-β secreted by a number of different 
cell types after flu infection, but mainly senescent cells, induces and reinforces the activation of Treg CD4 
T cells which, inhibits CD4 T cell effector function such as TH1 cells, which are important in directing 
responses necessary for viral clearance. This then results in prolonged viral exposure, enhanced 
inflammation, and delayed helper responses to recover from infection in aged mice. Although more 
research is underway to examine the exact mechanisms of inhibition, it is shown here that using 
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vaccination, senolytic drugs such as D+Q, or neutralizing antibody against TGF-β that the Treg responses 
are dampened and in the case of vaccination, balance between effector cell subsets are restored to levels 
seen in a young mouse. This figure was created with BioRender.com.  
 
 
It is demonstrated in this thesis that vaccination provides significant help to CD4 T cells 
during flu infection. In addition, it enhances the overall flu responses and dampens 
inflammation, reduces virus in the lungs, improves antibody generation, and helps reduce 
weight loss, and increases survival in aged mice. Moreover, this work shows that 
vaccination can aid in the control of dysregulated cellular responses by bringing levels of 
inflammatory and regulatory CD4 T cells down. The mechanism as to how vaccination 
provides this help to CD4 T cell regulation, however, has yet to be elucidated, but could 
be attributed to regulation of TGF-β secretion by some unknown mechanism. This work 
suggests that vaccination could induce help through a TGF-β dependent manner. In 
Figure 19, it is clear that vaccination reduced the amount of TGF-β in the BAL fluid from 
the lungs at early time points post infection. What would be interesting to see as a next 
step is if vaccination in aged mice has a subsequent effect on memory CD4 or CD8 T cell 
formation because the availability of TGF-β in the lungs has been shown to play an 
important role in memory formation (Ma and Zhang 2015; Zhang and Bevan 2013).  
 
In this work, TGF-β neutralizing mAb was administered to aged mice to determine if the 
effects seen in flu responses were due directly due to reduced TGF-β levels. As shown 
in Figure 21, cytokines and chemokines seem to be more regulated when TGF-β is 
reduced and Treg subsets are also down-regulated. These results could indicate a larger 
impact TGF-β has on the aged environment than thought before. More experiments are 
underway to examine the effects of TGF-β neutralization in aged mice in p16-3MR mice. 
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This would allow for a closer examination of the contribution of TGF-β in the senescent 
environment of the lungs and overall flu responses, such as flu-specific antibody 
measures and viral titers with or without senescent cells. These experiments are vital to 
understand the broad effect TGF-β could have in the aged environment not only on CD4 
T cells, but also within the tissue to promote anti-viral responses.  
 
As a therapeutic way to reduce senescent cells in the lungs, D+Q does provide a potential 
method for dampening Treg responses to have a balance in T helper subsets after flu 
and shows reduction in TGF-β in the BAL. Because senolytic drugs have a significant 
impact on both senescence cells and Tregs, however, it would be necessary to determine 
if the effects seen in the Treg population were due to the elimination of senescent cells, 
or to the drug itself. In this case, it would have been beneficial to administer D+Q to an 
uninfected young animal, with theoretically no senescent cells, to see if Treg subsets were 
also diminished in a tissue such as the spleen, or gut, which are known to have Treg cells. 
The demonstration that Tregs could be controlled, however, by the use of D+Q in aged 
mice is very useful and more testing on the effects of senolytics on CD4 T cells would 
have to be studied thoroughly in order to consider D+Q a useful treatment in altering the 
aged environment. It would also be interesting to determine if D+Q treatment enhanced 
IFN-α and IFN-β activation earlier in the flu response in aged mice. All of these pieces in 
conjunction with the CD4 T cell Treg suppression data shown here, would be additional 
novel findings, as D+Q has not yet been used in the context of infection in aged mice.  
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Finally, throughout this thesis work, an incredible amount of trouble shooting with the p16-
3MR mice was done. There are caveats to this model; one being it is relatively new and 
although the p16 construct is stable, the detection methods are still in preliminary phases. 
RFP expression can be difficult to determine without a large insult such as irradiation or 
other chemical inducers of senescence and even that produces variable results. The 
percentage of senescent cells, despite having shown to have a great effect in vivo and in 
vitro can be as small as 2-5% in some tissues. In the lung the percentage of senescent 
cells reaches an average of about 2% of the tissue using the flu infection model in mice. 
As a result, it is difficult to detect senescent cells by PCR or luminescence in such a small 
population in mice and the most effective means seemed to be flow cytometry, which 
does limit the ability to use the detection aspect of this mouse model in these studies.  
 
Another caveat is that the model of eliminating senescent cells in vivo using ganciclovir 
(GCV) was not able to be effectively studied in this thesis work due to the difficulties in 
inducing senescence in young p16-3MR mice and requires much more exploration and 
troubleshooting. Even further, with irradiation and using GCV to eliminate senescent cells, 
differences could not be seen in vivo as the variability was too great. An additional caveat 
to this model is that senescence elimination can only be done in the entire mouse.  
 
As artificial methods of senescence induction like irradiation or doxorubicin treatment 
proved to be too variable to be reliable, we moved to the naturally aging approach, which 
greatly increased the timetable for completion. This will be a much more stable model 
and better use of all three constructs in the 3MR model. What was also interesting was 
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the ability for the flu to induce senescence in the lung. The kinetics of this in young mice 
has never before been shown, especially using this 3MR model. It was most notable that 
the induction of senescence in the young mice only appeared two weeks post influenza 
infection and disappeared again before four weeks post infection. It will be very interesting 
to study if those senescent cells have any long term consequences in the lungs and if flu 
inflection can predispose an individual to developing increased senescence or Treg 
generation for subsequent infections.  
 
It would also be interesting to see if vaccinated p16-3MR mice were more resistant to 
senescence after subsequent infection. Based on this work, it would also be an important 
future direction to determine the effects of senescence cell elimination by using the HSK-
TV construct in the 3MR mouse model with administration of GCV as it would be the first 
ever research to examine the immune response in aged mice without senescent cells. 
While senescent cells are important for many processes, including wound healing, it is a 
possibility that deleting senescent cells would not allow aged mice to heal at all. 
Examining the effects seen in vaccination, shows that recovery from flu infection still 
happens with significantly low levels of TGF-β. Another point to consider however, is that 
TGF-β is not the only cytokine secreted by senescent lung cells. Eliminating all 
senescence associated signals would thus have an unknown effect on flu responses, 
which remains to be studied. Taken together, the work presented in this thesis provides 
many points of interest for continuing and future studies in the field of aging, senescence, 
and CD4 T cells.  
 
	 104	
Conclusion 
 
Although exact mechanisms of aberrant CD4+ T cell differentiation with aging remains to 
be determined, it is clear that this plays a strong role in poor flu infection responses in 
older individuals and aged mice. While many steps involved in CD4+ T cell priming and 
activation are impaired with aging, it had not been determined yet if one stage is more 
indicative of poor CD4+ T cell function over another or if, in fact, CD4+ T cell decrements 
can be overcome at all to significantly improve the aged response to flu. The research in 
this thesis work suggests that manipulating vaccine strategies or the aged tissue 
environment could promote better balanced CD4+ T cell subsets with aging and controlled 
inflammation. It is possible that a combination of preventative and prophylactic strategies 
will need to be used to effectively protect the elderly population from flu related morbidity 
and mortality.  
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MATERIALS AND METHODS 
 
Mice 
Young (2-3 months) C57BL/6 mice were were purchased from Jackson Laboratories or 
obtained from the National Institute on Aging. Aged (19-22 months) C57BL/6 mice were 
obtained from the National Institute on Aging rodent colony. All mice were housed in a 
climate controlled environment and fed standard rodent chow and water ad libitum. All 
mice were cared for in accordance with the recommendations in the Guide for the Care 
and use of Laboratory Animals of the National Institutes of Health. All procedures were 
approved by the University of Connecticut Medical School IACUC, protocol number 
100705. Breeding pairs of p16-3MR mice were gifted from the Campisi Laboratory at the 
Buck Institute. Mice were then bred in house in accordance with guidelines listed above.  
 
Viral infection 
Mice were anesthetized with isoflurane and intranasally inoculated with either 40uL, 50uL, 
or 70uL of influenza virus A/PR/8/34 (PR8), as specified, to receive a dose of 400, 500, 
or 700 EID50, respectively. Mice were weighed daily to monitor infection progression. 
Recumbent mice and mice that lost more than 30% body weight were considered 
moribund and euthanized. All mice underwent gross pathological examination at time of 
sacrifice and animals with obvious pathology were excluded from the study. 
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Flu Virus Quantitation 
At time points indicated, whole lung tissue was homogenized and RNA was isolated via 
TRIzol/chloroform extraction (Ambion by Life Technologies and Sigma Aldrich 
respectively). RNA was reverse transcribed with iScript cDNA synthesis Kit (Bio-Rad 
Laboratories, Inc., Hercules, CA) and flu viral copies were detected via reverse 
transcription quantification PCR of flu acid polymerase (PA). 
 
Multiplex 
Bronchiolar lavage fluid (BAL) was collected by flushing lungs with 1ml saline post 
mortem. Supernatant was collected after centrifugation and assayed for cytokine and 
chemokine content using the Luminex Mouse Cytokine/Chemokine 32-plex panel (EMD 
Millipore).  
 
Active TGF-β 1 ELISA. 
TGF-β1 was measured in the BAL supernatants using the LEGEND MAXTM Free Active TGF-β1 
ELISA kit (BioLegend). Samples were run in duplicate according to manufactures instructions.  
 
Albumin assay 
The albumin content in BAL supernatant was determined by ELISA (Bethyl Laboratories). 
 
Determination of antibody titers 
Blood was harvested post-mortem by cardiac puncture on days post-infection as 
indicated. The blood was allowed to coagulate for 30 minutes at room temperature, 
centrifuged (×10,000 rpm) 10 min at room temperature, and the serum was collected 
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and kept at -20ºC until analysis was performed. PR8-specific IgG was determined by 
ELISA using HRP-labeled anti-isotype antibodies (Southern Biotech Inc.). Antibody 
titers were determined by the last serum dilution with an optical density above 
background.  
 
Vaccination 
Recombinant A/PR/8/ influenza nucleoprotein (NP) was generated by the Protein 
Expression Core at UConn Health. Immunizations were prepared using NP protein and 
AddaVax (Invivogen) at 1:1. Injections were administered i.p. at a concentration of 30ug 
NP in 100uL per mouse. Control mice were given 100uL PBS. Mice received one dose 
of vaccination or control at 30 days and a second dose at 20 days prior to influenza 
infection.  
 
Flow cytometry 
Single cell suspensions were generated from spleens, lymph nodes and lungs of young 
and aged mice. Cells were incubated with Fc block (anti-CD16/32) for 15 min on ice 
followed by staining with NP311-325IAb MHC class II tetramer (generated by the NIH 
Tetramer Core Facility) for 1 h at room temperature at a dilution of 1:50 to ensure optimal 
staining. In experiments in chapter eight, as specified, this was followed by staining with 
anti-CD4 (eBioscience) and anti-Ly6C and anti-PSGL-1 (eBioscience). In transcription 
factor studies, anti-CD4 antibody was used in combination with NP CII Tetramer and 
transcription factor antibodies: Tbet (BioLegend), FoxP3 (BioLegend), Bcl6 
(eBioscience). For intracellular transcription factor detection, cells were fixed and 
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permeabilized using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) 
according to the manufacturer’s instructions. Endothelial cells were identified as being 
CD45-CD31+ (BD. Samples were acquired on LSR II flow cytometer (BD Biosciences), 
and data were analyzed with FlowJo software (Tree Star). 
 
Antibody treatments 
Passive transfer of mouse IgG2a NP-specific mAb H16-L10-4R5/HB-65 was achieved by 
administering 350 µg intraperitoneal injections on the day of and the day prior to PR8 
influenza challenge. Control mice received isotype matched mAb C1.18.4. All mAb were 
Protein G purified and supplied by BioXcell, who reported < 2 endotoxin units per mg. 
αTGF-β neutralizing antibody (clone: 1D11.16.8)  and IgG isotype matched control (clone: 
MOPC-21) was purchased from BioXell and administered on days 2, 4, 6, 8, and 10 post 
infection.   
 
D+Q treatments  
Mice were treated with 2mg/mL dasatinib and 20mg/mL quercetin per mouse 
administered for three consecutive days in two treatments. D+Q and vehicle are made in 
10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG. Solutions were left 
to sit rotating gently at room temperature for several hours to dissolve. Solution was 
stored at 4°C for 5 days or otherwise discarded in appropriate hazard material container. 
Drug was administered by oral gavage.   
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Statistics 
Survival curves were analyzed by log rank tests. In all other studies, differences between 
vaccinated and unvaccinated groups or between young and aged groups were analyzed 
by Student’s t-test or 2 or 3-way ANOVA with Bonferroni posthoc correction. Statistical 
analyses were performed with Prism 5, Prism 6, Prism 8 software (GraphPad Software 
Inc.) or SPSS Software (IBM). Differences were considered significant at p<0.05. 
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